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INTRODUCTION 
 
Thyroid neoplasms constitute the most common of all endocrine neoplasms and 
more than 95 % arise from follicular epithelial cells. They encompass a wide variety 
of benign and malignant tumours. The most common malignant tumour is papillary 
carcinoma with a frequency of 70 to 85 % with preponderance among young females.  
Historically, the identification of papillary carcinoma relied on the presence of 
papillary architecture. The current accepted diagnosis is based on the nuclear features 
that include optical clearing, overlapping, nuclear grooves and pseudoinclusions. 
However, identification of these features remains, at times controversial and the 
distinction of papillary carcinoma from its histological mimickers such as follicular 
adenoma and follicular carcinoma may sometimes be difficult.1 
Despite the propensity for lymphatic dissemination to the cervical lymph 
nodes, the majority of patients with these tumours, if appropriately treated, have an 
excellent long term prognosis compared to nonpapillary tumours. Hence it becomes 
mandatory to diagnose papillary carcinoma correctly for therapeutic purposes and for 
assessing the prognosis. Immunohistochemistry helps in the circumstances where 
cytological features do not suffice for differential diagnosis.2 
The present study aims at histologically classifying all thyroid neoplasms and 
to study its histomorphological characteristics and to evaluate the expression of 
immunohistochemical markers such as Cytokeratin 19 and thyroglobulin in cases of 
papillary thyroid carcinoma and its histological mimickers. 
1
 AIMS AND OBJECTIVES 
 
1. To record the incidence of thyroid neoplasms among surgical pathology 
specimens at Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai. 
 
2. To study the histomorphological characteristics of these neoplasms and subtype 
them according to the established classification systems. 
 
3. To compare the histomorphological profile of these cases with those reported 
in literature. 
 
4. To study the expression of immunohistochemical markers – Cytokeratin 19 and 
thyroglobulin in thyroid neoplasms. 
 
5. To determine the usefulness of immunohistochemistry in differentiating 
Papillary thyroid carcinoma and its variants from its histological mimickers. 
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REVIEW OF LITERATURE 
 
Thyroid neoplasms constitute the most common type of endocrine neoplasms 
and more than 95% arise from follicular epithelial cells while a few arise from 
parafollicular C cells. The most common benign thyroid neoplasm is follicular 
adenoma.3 Malignant tumours of the thyroid are less common but Papillary thyroid 
carcinoma is the most common type, though rarely other types also occur. The WHO 
classification of thyroid neoplasms is given in Annexure II. 
 
BENIGN NEOPLASMS 
 
FOLLICULAR ADENOMA 
It is the most common thyroid neoplasm and is defined as a benign 
encapsulated tumour showing evidence of follicular cell differentiation.4 It occurs 
most frequently in adults aged 20 to 50 years, more common in females than males.  
Grossly, ranging from 1 to 3 cm, well demarcated with a thin intact fibrous 
capsule with homogenous gray white to red cut surface depending on cellular 
composition and colloid content.5 Secondary changes like hemorrhage, calcification or 
cystic degeneration may be seen. Massive necrosis is sometimes seen as a 
complication of FNAC. 
Microscopically, they are sub-classified according to the architectural 
differentiation of the follicle and colloid content within the neoplasms. 
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1. Trabecular/Embryonal/Solid: Little follicle formation with little or no colloid 
resembling the thyroid tissue during prefollicular embryonal stage of intra-uterine life. 
2. Fetal/Microfollicular: Microfollicles with small amount of colloid. 
3. Simple/Normofollicular: Well developed follicles with normal colloid content. 
4. Colloid/Macrofollicular: Large follicles with excess colloid. 
5. Hurthle Cell: Follicles are lined by Hurthle cells which are large cells with intense 
eosinophilic granular cytoplasm. 
In most instances, more than one architectural patterns are seen in follicular 
adenoma. There is no clinical significance attributable to the different subtypes of 
follicular adenoma. 
There is a single layer of lining follicular cells with eosinophilic to amphophilic 
cytoplasm, distinct cell borders, uniform round to oval nuclei. Mitosis is not usually 
seen.  
Follicular adenomas have a complete fibrous capsule varying in thickness. In a 
study by Koren R et al,6 utilizing picrosirius orange-red (PSR) staining techniques for 
the evaluation of the capsular collagen have found differences in the staining 
characteristics of capsular collagen in follicular adenoma and follicular carcinoma 
which may help in the differential diagnosis. 
Hyperplastic changes in the form of papillary or pseudopapillary structures 
may be seen. They are short papillae with ill-defined fibrovascular core, with no 
cytological features of papillary carcinoma.  
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Elder S et al7 showed that histomorphometrically guaged nuclear parameters of 
the tumor cells such as the nuclear area, diameter, and nuclear irregularity factor of the 
follicle may help differentiation. In majority of cases the measurements of these 
parameters reliably allocated the tumor to benign versus malignant categories. 
 
VARIANTS OF FOLLICULAR ADENOMA: 
1. Follicular adenoma of Oxyphilic cell type (Oncocytic or Hurthle cell adenoma) 
2. FA with papillary hyperplasia (Papillary variant of FA) 
3. Signet-ring cell adenoma.  
4. Mucinous follicular adenoma. 
5. Lipoadenoma. 
6. Adenochondroma. 
7. Clear cell follicular adenoma. 
8. Toxic (Hyperfunctioning) adenoma. 
9. Atypical adenoma. 
10. Follicular adenoma with bizarre nuclei. 
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HYALINISING TRABECULAR TUMOUR 
It is a rare tumour of follicular origin with a trabecular pattern of growth and 
marked intratrabecular hyalinisation. 
Carney et al.8 in 1987 first coined the term hyalinizing trabecular adenoma 
(HTA) while describing a series of 11 encapsulated tumors microscopically showing 
polygonal and fusiform cells arranged in trabeculae separated by thin capillary 
network and hyalinized amyloid-like stroma which is often calcified. The cells are 
negative for calcitonin. This pattern is similar to that of a paraganglioma  
(Paraganglioma like adenoma of the thyroid). 
The cells within the trabecular islands occasionally show longitudinal nuclear 
grooves, nuclear pseudoinclusions, psammoma bodies, and paranuclear yellow 
cytoplasmic bodies.9 In view of these nuclear features, which resemble papillary 
carcinoma, Cheung CC et al10 suggested that HTA may a variant of papillary 
carcinoma since RET/PTC rearrangement has been reported in HTA which suggests 
its similarity to PTC at the molecular level.  
A study by Fonseca E et al12 showed similarities in cytokeratin immunoprofile 
between papillary carcinoma and HTA, especially CK19 which was positive in both.11 
But the study by Hirokawa et al. showed that HTAs were all CK-19 negative, while 
papillary carcinomas were positive. A study by Galgano MT et al13 reported lack of 
CK 19 and HBME-1 immunoreactivity in all their HTAs compared to diffuse positive 
staining noted in all papillary carcinomas. 
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In view of the nuclear features which resemble papillary thyroid carcinoma 
along with some studies reporting similar immunophenotype and the presence of 
RET/PTC gene rearrangement in HTA, WHO in 2004 reclassified these tumors as 
HTT, which clearly emphasizes the uncertain biologic behavior of these tumors.3  
Gowrishankar S et al14 reported a case of hyalinizing trabecular carcinoma 
presenting as lung metastasis with evidence of vascular invasion and showing some 
nuclear groves and rare pseudoinclusions. The tumor was negative for CK19. 
 
MALIGNANT NEOPLASMS 
 
PAPILLARY CARCINOMA OF THYROID 
Papillary carcinoma is defined as a malignant epithelial tumour showing 
evidence of follicular cell differentiation, and characterised by distinctive nuclear 
features.3 
It is the most common form of thyroid malignancy comprising 75 to 85 % of 
all malignant thyroid tumours, with male to female ratio of 2:1, occurring at any age, 
mean being 40 years. They tend to be biologically indolent and have excellent 
prognosis.15,16 These tumours metastasize via lymphatics; vascular invasion can also 
be seen. 
Gross: They typically present as firm to hard white-tan tumors with invasive borders 
with a granular cut surface resulting from the presence of papillae. The presence of 
psammoma bodies can impart a gritty sensation while cutting. Tumors with 
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predominantly follicular architecture are often tan-brown and fleshy, similar to 
follicular neoplasms. Some tumors can be encapsulated. Cystic change can occur. 
Multifocal disease is common in about 65% of cases.17 
Microscopic features: Microscopically, the diagnosis is based together on 
characteristic cytological and architectural features. 
Cytological features: 
Nuclear features of follicular cells are important in diagnosing Papillary 
carcinoma. The nuclei are typically large, crowded, ovoid, ground glass (Orphan 
Annie eyed) and grooved with small distinct nucleoli and nuclear pseudoinclusions. 
Orphan Annie eyed nuclei refers to the empty looking nuclei with scanty 
marginated dusty chromatin seen as an artefact in paraffin sections in more than 80% 
of cases. The chromatin material is apposed to the inner surface of the nuclear 
membrane, which looks thickened with an irregular inner contour. However this 
feature is not pathognomonic, since benign lesions such as nodular hyperplasia, 
follicular adenoma, Graves disease and Hashimoto’s thyroiditis can exhibit clear 
nuclei focally.18  
The nuclear groove, formed by deep infolding of the nuclear membrane along 
the longitudinal axis of the oval nucleus, is found in almost all cases of papillary 
carcinoma, at least focally. Yet, nuclear grooving is not pathognomonic since it can 
also be observed in solid cell nests, follicular neoplasms, hyalinizing trabecular 
adenomas, poorly differentiated thyroid carcinomas and adenocarcinomas of non-
thyroid origin.19,20 
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Nuclear pseudoinclusions, representing intranuclear cytoplasmic herniation 
pockets, are typical but not pathognomonic, are found only in a minority of tumor 
cells.21 
In some cases, the nuclear features may not be well developed or occur only 
focally. In such cases, the diagnosis depends on the architectural features or 
identification of foci showing the typical nuclear features. 
The neoplastic cells are polygonal to cuboidal with lightly eosinophilic to 
amphophilic cytoplasm but can be oxyphilic or clear.22,23 Stroma may show 
calcification or ossification.24 Cytoplasmic mucin can be demonstrated in a proportion 
of cases by histochemical stains.25 Focal squamous differentiation is seen in some 
cases and such foci usually do not exhibit the characteristic nuclear features of 
papillary carcinoma. 
Psammoma bodies are seen in about 25% of cases. They are roughly spherical, 
basophilic, non-birefringent, concentrically layered calcium deposits and are located 
in the epithelium covering the stalks of the papillary tumors and in the sessile masses 
of epithelium that form the lining of cystic spaces in these growths. At times, they are 
seen in the core of the papillary stalk and are occasionally free in colloid lakes. 
Architectural features: 
The characteristic feature is a complex branching papillary pattern with a well 
defined stalk and delicate fibrovascular stroma lined by neoplastic epithelial cells. 
The papillae seen in nodular goiter and follicular adenoma with papillary 
hyperplasia are usually broad with follicles in the cores. The lining cells appear 
columnar with regular, non crowded, basally situated, dark, round nuclei resembling 
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beads on string which is in striking contrast to the crowded and haphazardly oriented 
pale nuclei of papillary carcinoma. 
The papillae in thyrotoxicosis, Hashimoto’s thyroiditis and toxic follicular 
adenoma are non branching short, stubby projections that protrude into the follicular 
lumen and without well defined fibrovascular cores. In Hashimoto’s thyroiditis well 
developed nuclear features of papillary carcinoma are lacking although focal nuclear 
clearing may be seen.  
Hurthle cell adenoma/carcinoma may have a minor papillary component. The 
papillae are usually non arborizing and the cells do not show nuclear crowding. 
However occasional nuclear grooves may be present.  
The majority of papillary carcinomas contain some portion of follicular 
elements or purely follicular elements. The mixture of follicular structures does not 
alter the biological behaviour or prognosis of neoplasm. 
Other common patterns include complex tubulopapillary, microglandular, 
cribriform, anastomosing tubular, trabecular and solid patterns. 
 
 
VARIANTS OF PAPILLARY CARCINOMA 
While the characteristic nuclear features are common to all histological types 
of papillary carcinoma, there are a number of variants which have been described on 
the basis of the size or architectural patterns of the tumour. The diagnosis of some of 
these variants is important since some may behave in a more aggressive fashion 
compared to the conventional papillary carcinoma 
. 
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TABLE 1: VARIANTS OF PAPILLARY CARCINOMA 
 PTC VARIANT DEFINING MORPHOLOGIC 
FEATURES 
MIMICKERS CLINICAL SIGNIFICANCE 
 
Less aggressive (Better prognosis) variants 
1. Papillary 
microcarcinoma26 
Incidentally discovered 
small papillary carcinoma 
<1 cm size 
Fibrosing thyroiditis 
Hyperplastic 
adenomatoid nodule 
Highly favorable 
prognosis27,28; 
unfavorable outcome 
when lymphadenopathy 
>3 cm and a 
nonencapsulated type of 
primary lesion29 
2. Encapsulated follicular 
variant 
Encapsulated tumor 
composed almost 
exclusively of follicles 
Follicular adenoma  
Follicular carcinoma 
Highly favorable 
prognosis: no tumor 
relapse after excision 
 
Variants with behaviour similar to the conventional type 
3. Follicular variant  Composed almost 
exclusively of follicles, with 
abortive papillae; colloid 
often dark-staining 
Follicular adenoma 
Follicular carcinoma 
No prognostic 
implications 
4. Macrofollicular variant Presence of many large-
sized follicles in >50% of 
tumour30 
Nodular goiter No prognostic 
implications 
5. Solid variant >50% of tumor showing 
solid growth pattern31,32 
often traversed by delicate 
fibrovascular septa 
Poorly differentiated 
(insular) carcinoma  
Medullary carcinoma 
Slightly higher frequency 
of distant metastasis and 
less favourable prognosis 
compared with 
conventional PTC 
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 PTC VARIANT DEFINING MORPHOLOGIC 
FEATURES 
MIMICKERS CLINICAL SIGNIFICANCE 
6. Oxyphil cell (Oncocytic, 
Hürthle cell) variant 
>50% of tumor cells with 
abundant oxyphilic 
cytoplasm33 
 
Hürthle cell adenoma  
Hürthle cell 
carcinoma 
No prognostic 
implications 
7. Clear cell variant Extensive cytoplasmic 
clearing of tumour cells 
(accumulation of 
glycogen)34 
 
Intrathyroidal 
parathyroid tumor  
No prognostic 
implications 
8. Cribriform morular 
variant 
Intricate admixture of 
cribriform pattern, small 
follicles, papillae & 
squamoid morules; colloid 
usually absent 
 
 
Columnar cell 
carcinoma 
Tall cell variant of 
papillary carcinoma 
Familial adenomatous 
polyposis should be 
excluded;35,36 by itself, it 
has no prognostic 
implications37 
9. Warthin tumor–like 
variant38 
Broad papillae lined by 
oxyphilic neoplastic cells, 
with the cores packed with 
lymphoplasmacytic 
infiltrates 
 
Hashimoto’s 
thyroiditis 
No prognostic 
implications39 
10. Variant with exuberant 
nodular fasciitis like 
stroma40 
Presence of abundant 
nodular fasciitis like or 
fibromatosis like reactive 
stroma amidst the papillary 
carcinoma component 
 
 
Nodular fasciitis 
Fibromatosis 
Benign mesenchymal 
neoplasm 
No prognostic 
implications41 
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 PTC VARIANT DEFINING MORPHOLOGIC 
FEATURES 
MIMICKERS CLINICAL SIGNIFICANCE 
11. Papillary carcinoma 
with lipomatous 
stroma 
 
Adipose cells found within 
the papillary carcinoma42 
— No prognostic 
implications 
12. Variant with spindle 
cell metaplasia 
Component of short 
fascicles of bland looking 
spindled tumor cells 
merging into the papillary 
carcinoma component43 
Dedifferentiated 
papillary carcinoma 
— 
 
More aggressive (Worse prognosis) variants 
 
13. Diffuse follicular 
variant 
Diffuse involvement of 
entire thyroid without 
formation of discrete tumor 
nodules and composed 
entirely of follicles 
 
Colloid goiter More aggressive 
Frequent lymph node and 
distant metastases44 
14. Trabecular variant >50% of tumor showing a 
trabecular growth pattern 
Follicular adenoma 
or carcinoma, 
trabecular 
(embryonal) type  
 
Less favourable outcome 
15. Tall cell variant18 Composed predominantly 
of cells whose heights are 
at least three times their 
widths; tumor cells often 
with oxyphilic cytoplasm 
Columnar cell 
carcinoma 
More aggressive 
Larger tumors 
More frequent 
extrathyroidal extension 
Higher recurrence rate 
Higher mortality 
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 PTC VARIANT DEFINING MORPHOLOGIC 
FEATURES 
MIMICKERS CLINICAL SIGNIFICANCE 
16. Diffuse sclerosing 
variant 
Diffuse extensive 
involvement of one or both 
lobes with sclerosis and 
lymphoplasmacytic 
infiltration; tumor islands 
often small and dispersed, 
commonly showing 
squamous metaplasia and 
prominent psammoma 
body formation 
 
Thyroiditis, 
especially because 
of the diffuse nature 
of the process and 
frequent presence 
of serum 
antithyroglobulin or 
antimicrosomal 
antibodies 
More aggressive 
Frequent lymph node and 
distant metastases45 
17. Dedifferentiated 
papillary carcinoma 
Coexistence of PTC with 
undifferentiated or poorly 
differentiated carcinoma 
indicating transformation to 
higher grade neoplasm  
 
— Worse prognosis 
High mortality rate 
 
*All variants show the typical nuclear characteristics of papillary carcinoma, at least in some area of the tumor. 
 
In a study by Roti E et al,28 tumor size more than 0.8 cm was associated with 
more aggressive disease. However, in a recent meta-analysis study by Elio R et al,29 
significant risk factors for recurrence included younger age group, clinically overt 
tumor, multifocality, and lymph node involvement at diagnosis; tumor size was not 
associated with recurrence. 
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Follicular variant, the most common variant of papillary carcinoma, has 
generated a lot of controversy in its diagnosis. While PTC with a recognised follicular 
pattern was observed as early as 1953, the term FVPTC was first proposed by Lindsay 
in 1960,46 and was, at that time, still regarded as a type of follicular carcinoma. In 
1974, the WHO recognized the entity as Follicular variant of papillary carcinoma in 
its histological classification of thyroid tumors. 
In a study by Liu J and Singh B et al, FVPTC with an infiltrative and 
noncapsulated pattern showed significantly higher rate of regional lymph node 
metastasis (65% vs. 5%), intratumoral fibrosis (88% vs. 18%), exrathyroidal extension 
(65% vs. 5%), and positive margins (50% vs. 2%) compared to encapsulated tumors.47 
One of the most challenging and controversial diagnoses in thyroid pathology 
may be the identification of focal nuclear changes of PTC in encapsulated follicular 
patterned lesions48 with a tendency to overdiagnose FVPTC.49 
As the nuclear changes may not be diffuse, they can sometimes be 
misdiagnosed as follicular adenoma. The nuclear changes are most often seen in the 
subcapsular region of the tumor.50 The importance of diagnosing these lesions as 
encapsulated FVPTC is important since these tumors may later present with bone 
metastases some even 15–17 years after initial diagnosis justifying their appropriate 
treatment at the time of presentation.51 In view of this difficulty in their diagnosis, 
some have suggested that encapsulated follicular lesions with doubtful nuclear 
changes should be diagnosed as well differentiated tumor of uncertain malignant 
potential (WDTUMP).48  
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PROGNOSTIC FACTORS IN PAPILLARY CARCINOMA 
The overall 5 year survival rate for papillary thyroid carcinoma is 96 to 97% 
with a 10 year survival rate of 93%.52 For a more specific prognosis for individual 
cases, there are at minimum 13 known scoring systems for prognosis;53 among the 
more often used are given in Annexure IV. 
 
FOLLICULAR CARCINOMA 
Follicular carcinoma is a malignant tumor of the thyroid follicular cells 
showing a follicular architecture and without the characteristic nuclear features of 
PTC.3 Comprising 5 to 10 % of all thyroid cancers, it is more aggressive than PTC, 
occurs in a slightly older age group and less common in children.5 
Capsular and vascular invasion are characteristic and so, distant metastasis is 
common. Lung, bone, liver, bladder and skin are the potential sites of distant spread. 
Lymph nodes are less commonly involved. 
 
(a) Minimally invasive follicular carcinoma
54,55 
This is a grossly encapsulated tumor with a pattern of growth resembling that 
of an adenoma. The diagnosis of malignancy depends entirely on the demonstration of 
blood vessel invasion and or capsular invasion on histology. The vessel should be of 
venous caliber and located immediately outside the capsule and should contain one or 
more clusters of malignant cells attached to the wall and protruding into the lumen.3 
The tumor expands in a mushroom like fashion in the adjacent area of capsular breach 
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with an occasional formation of second capsule in the advancing edge of the tumor. 
WHO defines capsular invasion as penetration through the capsule unassociated with 
previous FNAC.3 
In situations of questionable capsular breach, the terms “Follicular tumor of 
uncertain malignant potential (FT-UMP)” is used when the characteristic nuclear 
changes of papillary carcinoma are absent48 and “Well differentiated tumor of 
uncertain malignant potential” is used when the changes are questionable. Thomson 
et al.56 in a series of 95 cases of minimally invasive follicular carcinoma, which 
included cases both with capsular and/or vascular invasion, showed excellent survival.  
Distant metastases are seen more often in tumors with vascular invasion, thus it 
may be best to regard this as a distinct group when evaluating the prognosis.57 The 
differential diagnosis includes other follicular patterned lesions such as follicular 
adenoma, FVPTC, and hyperplastic colloid nodule. 
 
(b) Widely invasive follicular carcinoma
54,55 
Macroscopically, the tumor has widely invasive edges with necrotic foci. 
Microscopy shows a follicular tumor, usually with solid or trabecular areas with 
invasion of the surrounding thyroid parenchyma, high mitotic rate and necrosis. There 
are complete or multifocal areas of capsular invasion, and vascular invasion. These 
tumors spread to distant organs through blood vessels and up to 80% can develop 
systemic metastases. The prognosis being much worse than MIFC, the 10 year 
survival is 25 to 45% as opposed to 70 to 100% in the MIFC group.3 
17
 
 
 
VARIANTS OF FOLLICULAR CARCINOMA 
(a) Follicular carcinoma, oncocytic variant (Hurthle cell carcinoma) 
It is a rare thyroid malignancy representing fewer than 5% of all differentiated 
thyroid carcinomas.58 The male to female ratio is 1:7 and mean age is 52.6 years. In 
the WHO classification, this is classified as a subtype of follicular carcinoma. Now, 
many authors consider this as a distinct clinical entity, which is histologically in the 
group of well-differentiated carcinomas since they have a different oncogenic 
expression than follicular carcinomas.59  
Grossly, the tumor may be solitary or multiple solid tan, well-vascularised, well 
encapsulated or lobulated unencapsulated. Microscopically, tumors show patterns like 
solid or trabecular. They are composed predominantly of oxyphil cells. The diagnosis 
of malignancy is reliably based on histologic evidence of capsular or vascular 
invasion, extrathyroidal local tissue invasion and nodal or distant metastasis.  
Hurthle cell carcinomas do show some differences from conventional follicular 
carcinoma.60 They appear to be more aggressive and show a higher tendency to 
metastatize to regional lymph nodes. They generally take up radioactive iodine less 
satisfactorily. Thyroglobulin immunoreactivity is weak and patchy. 
The differential diagnosis includes Hurthle Cell adenoma, Oncocytic variant of 
PTC and Oncocytic variant of Medullary Thyroid carcinoma. 
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TABLE 2: IHC MARKERS IN HURTHLE CELL CARCINOMA AND MTC 
IHC MARKERS61 HURTHLE CELL CARCINOMA MEDULLARY CARCINOMA 
Cytokeratin, CEA & TTF-1 + + 
Thyroglobulin + - 
Calcitonin - + 
Synaptophysin & Chromogranin - + 
S100, HMB45 & EMA + - 
 
(b) Clear cell variant of follicular carcinoma 
It is a rare variant with predominant clear cells that contain glycogen, mucin, 
lipid or dilated mitochondria. Vascular and/or capsular invasion is the only criteria to 
distinguish it from clear cell variant of follicular adenoma. Differential diagnosis 
includes metastatic renal cell carcinoma in which there are multiple nodules, clear 
cytoplasm, sinusoidal blood vessels or fresh hemorrhage. 
 
POORLY DIFFERENTIATED THYROID CARCINOMA 
It shows histologic and biologic features intermediate between well 
differentiated thyroid carcinomas and undifferentiated carcinomas. It is more common 
in women and in patients older than 50 years. Some of these tumours arise from pre-
existing papillary and follicular thyroid carcinomas, others most likely arise de novo. 
Gross Features: Most are more than 3 cm diameter and are solid and gray white with 
frequent foci of necrosis and pushing borders and rarely a thick capsule and rarely, 
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satellite nodules may be seen. Extrathyroidal spread is less common compared to 
undifferentiated carcinomas.3 
Microscopic features: Three different histologic patterns (insular, trabecular and 
solid) are seen with infiltrative pattern of growth, necrosis and vascular invasion.62 
The insular pattern is characterised by well defined nests of tumour cells 
surrounded by thin fibrovascular septa with artefactual clefts. Tumour cells are small 
uniform with round hyperchromatic or vesicular nucleus with indistinct nucleoli with 
increased mitotic figures. 
The trabecular pattern is characterised by tumour cells in cords or ribbons. 
The solid pattern shows large sheets of tumour cells occasionally showing 
small abortive follicles or colloid droplets. 
Hiltzik et al. defined PDTC on the basis of mitosis (5 or more per 10 HPF) and 
necrosis and found those criteria to identify a more aggressive subtype of thyroid 
carcinoma independent of the growth pattern.63 
Turin proposal64 for the diagnosis of Poorly differentiated thyroid carcinoma: 
 Presence of solid/trabecular/insular growth pattern 
 Absence of nuclear features of PTC 
 Presence of at least one of the following: 
o Convoluted nuclei 
o Mitotic activity of 3 or more per 10 HPF 
o Tumor necrosis 
20
 
 
ANAPLASTIC (UNDIFFERENTIATED) THYROID CARCINOMA 
Anaplastic carcinoma, a highly aggressive and rare thyroid tumor, accounts for 
1.7% of all thyroid malignancies.3 
The patients are usually elderly in their seventh or eighth decade of life with a 
female preponderance of around 2.5:1 and presenting with rapidly enlarging thyroid 
mass or a metastatic tumour in the cervical lymph nodes or distant sites with frequent 
pressure symptoms  such as dysphagia, hoarseness, and stridor. 
Grossly, the tumour is usually large, fleshy and often replacing the entire 
thyroid with areas of necrosis and hemorrhage with frequent infiltration of 
perithyroidal soft tissues. 
Microscopically, highly pleomorphic large polygonal, ovoid or spindle shaped 
tumour cells in diffuse sheets, irregular islands and cords with high mitiotic rate and 
necrosis with tendency to infiltrate and replace the walls of vessels obliterating the 
lumen. They are commonly admixed with neutrophils. A component of papillary, 
follicular or poorly differentiated thyroid carcinoma may be found in 50% of cases 
suggesting that anaplastic carcinoma may arise through a process of dedifferentiation.  
Thyroglobulin staining is variable ranging from 9 to 71% cases and is usually 
focal and weak; Thyroid transcription factors 1 and 2, two other markers of thyroid 
differentiation, may also be variable, and in the study by Nonaka D et al,65 were 
positive in 18 and 7%, respectively.65 The prognosis is extremely poor with 5-year 
survival ranging from 0 to 14%. 
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MEDULLARY THYROID CARCINOMA 
It is defined as a malignant thyroid tumor showing evidence of C-cell 
differentiation. It comprises 5 to 10 % of all cases of thyroid malignancies.3 
Approximately 80% of the medullary carcinomas occur sporadically.66 Most 
are unilateral with no associated C-cell hyperplasia in the rest of the gland. 
In the familial form, the tumor often develops at an earlier age, multicentric 
and often bilateral. There is usually an associated background of C-cell hyperplasia.67 
Gross features 
It usually lacks a capsule, but well demarcated, with lobulated outer contour 
and shows bulging, gray white or tan cut surface. Some are ill defined, hard and 
sclerotic with radiating contours. Older lesions may show calcification, bone 
formation, necrosis and hemorrhage. It affects the middle third of the lateral lobe 
where the C-cell density is highest. Rarely a thick fibrous capsule may sometimes be 
seen and may sometimes be associated with cystic and papillary change.68 
Microscopic features 
It is composed of sheets, nests or trabeculae of polygonal or plump spindle 
cells characteristically traversed by delicate fibrovascular septae, whorling or 
pseudopapillary pattern can be observed. Cellular dehiscence is common. The nuclei 
are round or oval and typically possess finely stippled chromatin and indistinct 
nucleoli. The cytoplasm is finely granular and often argyrophilic. Cytoplasmic mucin 
is demonstrable in 40-50% of cases. 
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Occasionally tumor cells may assume signet-ring appearance. Amyloid 
deposition is seen in 15 - 20% of cases as pink-staining amorphous material in the 
form of globules, may show calcification and foreign body giant cell reaction. 
 
Medullary carcinoma variants include the following:3 
1. Papillary/Pseudopapillary variant 
2. Follicular/Glandular variant 
3. Giant cell variant 
4. Spindle cell variant 
5. Small cell variant 
6. Neuroblastoma like variant 
7. Paraganglioma like variant 
8. Oncocytic variant 
9. Clear cell variant 
10. Angiosarcoma like variant 
11. Squamous cell variant 
12. Melanin producing variant 
13. Carcinoid like variant 
 
Presence of all these variants makes medullary carcinoma the great mimicker 
of other thyroid carcinoma; therefore, immunohistochemistry should be performed in 
all cases when the diagnosis is in doubt or some atypical features are present. 
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Immunohistochemical staining reveals positivity for calcitonin, chromogranin, 
whereas S-100 and HMB-45 was only positive in pigmented cells and negative for 
thyroglobulin. It is associated with RET point mutation which may sometimes behave 
as a dominant oncogene for thyroid follicular cells which may explain association of 
MTC with papillary thyroid carcinoma in some cases.69 
 
MEDULLARY MICROCARCINOMA 
Medullary carcinoma measuring less than 1 cm is called Medullary 
microcarcinoma. They are rare lesions comprising 0.15% of all thyroid carcinomas. 
Most often clinically latent, an elevated calcitonin levels helps in early diagnosis. 
Familial forms are common which are usually associated with C-cell hyperplasia. 
Nodular C-cell hyperplasia should be differentiated from microcarcinoma. 
Extension of C-cells through defects in the follicular based lamina and the infiltration 
of the thyroid interstitium are regarded as criteria to diagnose malignancy. 
 
MIXED MEDULLARY - FOLLICULAR CELL CARCINOMA 
Hales et al,69 in 1982, described an unusual carcinoma of thyroid that showed 
predominant medullary carcinoma admixed with areas of follicular differentiation. 
Both patterns prevailed at the primary site and also at the lymphnode metastasis. 
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These tumors may represent another entity-collision tumor, which can occur in 
two forms: 
1. Follicular carcinoma + Medullary carcinoma 
2. Papillary carcinoma + Medullary carcinoma 
The two components are either side by side or are intermingled. Each primary 
tumor exhibits only one line of cell differentiation, however, the metastatic deposits in 
lymphnode contain both elements abutting each other and resemble mixed tumor. This 
apparent dual differentiation in the metastasis should also be regarded as a collision 
phenomenon. A common tumorigenic stimulus which triggers the neoplastic 
transformation of both C-cells and follicular epithelial cells could be a possible 
explanation for such a phenomenon. 
 
RARE TYPES OF THYROID CARCINOMAS 
 
COLUMNAR CELL CARCINOMA 
It is a rare aggressive thyroid neoplasm, characterised by mixed papillary, 
complex glandular, cribriform and solid patterns. The papillae and glands are lined by, 
tall columnar cells with pseudostratified hyperchromatic oval or elongated nuclei. 
Subnuclear vacuoles and cytoplasmic clearing may be seen.  
It differs from the tall cell variant of papillary carcinoma by greater height of the 
cells, nuclear pseudostratification, nuclear hyperchromasia and lack of oxyphilic 
change in the cytoplasm.17 
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MUCOEPIDERMOID CARCINOMA 
It is a rare low grade malignant non-circumscribed tumor with islands of cells 
in a sclerotic background with areas of squamoid and mucin secretion. Areas of 
cribriform pattern, with elongated lumina containing colloid-like material are seen. 
Occasional papillae may be found. Mild to moderate nuclear pleomorphism with pale 
nuclei will be seen. Comedo-type necrosis and psammoma bodies may be seen.17 
 
SCLEROSING MUCOEPIDERMOID CARCINOMA WITH EOSINOPHILIA 
It is rare, low grade malignant tumor occurring in a background of Hashimoto 
thyroiditis, possibly arising from metaplastic squamous epithelium. 
 
MUCINOUS CARCINOMA 
Primary mucinous carcinoma of thyroid is extremely rare and is identical to 
mucinous/colloid carcinoma of other sites. 
 
SPINDLE EPITHELIAL TUMOR WITH THYMUS-LIKE 
DIFFERENTIATION (SETTLE) 
Also known as intrathyroid spindle cell tumour with mucous cysts, it is a rare 
tumour thought to be derived from ectopic thymus or branchial pouch remnant. The 
tumor cells stain positive with cytokeratin and muscle specific actin while they are 
negative for thyroglobulin and calcitonin.70 
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CARCINOMA SHOWING THYMUS LIKE ELEMENTS (CASTLE) 
Histologically identical to thymic carcinoma, it usually involves the lower pole 
of thyroid and adjacent extrathyroidal tissues with regional lymph node metastasis in 
about one third of the cases. The neoplastic cells are immunoreactive for cytokeratin 
and p63, but not thyroglobulin, calcitonin or TTF-1. Like thymic carcinomas, CD5 
and CD117 are always expressed.17 
 
NONEPITHELIAL TUMOURS 
Non epithelial tumours of the thyroid gland include: 
1. Primary lymphoma of thyroid 
2. Plasmacytoma 
3. Angiosarcoma 
4. Solitary fibrous tumour 
5. Smooth muscle tumours 
6. Paraganglioma 
METASTATIC CARCINOMA 
Metastases to thyroid from another primary source are infrequent; tumors that 
most commonly spread to the thyroid include kidney, breast, and lung carcinoma. 
Metastatic carcinoma has to be considered in the differential diagnosis of poorly 
differentiated carcinoma especially when there is non-insular pattern, and 
clinicopathological correlation and thyroglobulin immunostaining may be of help in 
these situations.17 
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IMMUNOHISTOCHEMISTRY 
  
Immunohistochemistry is used to determine the expression of a particular 
antigen and its microanatomic location in the tissue. It involves binding of primary 
antibody to the antigen of interenst in the tissueand then, the detection of the bound 
antibody using a chromogen. The differences in the immunoreactivity for particular 
antigens help to identify the lineage or the differentiation of the cells. 
 
Thyroglobulin 
It is the primary product synthesised in the thyroid and is a highly sensitive 
histogenetic marker for follicular cell origin. Staining may be patchy in the less well 
differentiated tumours. It is expressed in tumours of follicular cell origin and is absent 
in medullary carcinoma. 
 
Cytokeratin 19 
It is a type I intermediate filament protein and is the smallest known keratin 
and is unique that, compared to other keratins, it does not have a designated partner 
for the formation of filaments, implying that the regulation of its expression is 
different from other keratin encoding genes.71 
 
Immunohistochemical diagnosis of Papillary carcinoma and its mimics 
Until today, the gold standard for the diagnosis of follicular lesions particularly 
PTC is histology. Some of the ancillary studies such as immunohistochemistry and 
molecular techniques may be helpful, but none of them is conclusive.71 
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Papillary carcinoma typically stains for thyroglobulin and TTF-1. Expression 
of a variety of markers such as HMWCK (34βE12), CK19, Galectin 3, HBME1, Leu7 
(CD57), CITED 1, fibronectin 1, CD15 (LeuM1) or CD44, singly or in combination, 
has been suggested to be of value in the diagnosis of papillary carcinoma versus 
benign thyroid lesions or other thyroid tumours, but these markers are not totally 
specific, and the staining can be patchy and weak even in classical PTC.  
 
CK19 has been shown to be a sensitive marker for PTC, usually resulting in 
diffuse positivity in 80 to 100% of cases.1 Since CK19 detection in FA and FTC is 
often absent or less intense and weaker than in PTC, this has become one of the most 
commonly used marker to investigate thyroid lesions. Several authors emphasize the 
importance of the distribution and intensity of CK19 staining as the most critical 
aspects of accurate interpretation. The finely dispersed positivity seen in the cells of 
PTC is distinctive. Although this feature is usually diffuse throughout the lesion, focal 
staining for CK19 does not rule out a diagnosis of PTC, particularly in nodules with 
nuclear features of PTC that are seen focally.  
 
CK19 is also considered by many investigators to be a useful ancillary tool for 
the diagnosis of PTC in FNAC and in cell block preparation, especially in 
cytologically suggestive but indeterminate cases. The reported sensitivity and 
specificity using CK19 as a single marker is as high as 92% and 97% respectively. A 
panel of markers including CK19 and Galectin-3 was reported as reaching 100% of 
both specificity and sensitivity in the diagnosis of PTC.72 
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Mustafa Kosem et al,2 in their immunohistochemical study showed that 
HBME-1 and CK19 are more valuable in the differential diagnosis of papillary 
carcinoma. The high sensitivity and specificity of HBME-1 makes it a good marker 
for the diagnosis of papillary thyroid carcinoma.  
 
Michel R Nasr et al73 suggested that a combination of HBME1 and CK19 
attains a high sensitivity and specificity for the diagnosis of PTC.  Raphael SJ et al74 
concluded that HMWCK and CK19 are useful in the distinction of PTC from FA, 
FTC and nodular hyperplasia.  
 
Dina El Demellawy et al71 found that a panel of CD56, CK19 and P63 is of 
value in the distinction of Papillary thyroid carcinoma from other thyroid follicular 
lesions. P63 is a specific but less sensitive marker for papillary thyroid carcinoma than 
CK19. CD56 is a more specific and sensitive marker than CK19, however it is a 
negative rather than a positive marker for PTC. E-cadherin is of no value in the 
diagnosis of thyroid follicular lesions/tumours. 
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 MATERIALS AND METHODS 
SOURCE OF DATA 
Cases of thyroid neoplasms reported in thyroid specimens received in the 
Institute of Pathology, Madras Medical College, Chennai from January 2009 to April 
2011 formed the material for this study. 
INCLUSION CRITERIA 
 All cases of thyroid neoplasms and few cases of nonneoplastic lesions 
mimicking papillary carcinoma histologically irrespective of the age and sex were 
included for the study. 
EXCLUSION CRITERIA 
Nonneoplastic lesions of thyroid except for the cases histologically mimicking 
papillary carcinoma. 
Cases with inadequate material from the tumour were not included in the study. 
METHOD OF DATA COLLECTION 
The clinical features such as age and sex of the patient and type of surgery 
done were noted. The details of gross characteristics of the tumor such as the number 
and size of nodules, circumscription, cut section and secondary changes like cystic 
degeneration, hemorrhage and necrosis were noted. 
The tissues were fixed in 10% formalin for 24 hours. After formalin fixation, 
multiple bits were taken from representative areas. They were processed for 
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 histopathological examination and paraffin blocks were made. The blocks were cut at 
4 to 5 microns thickness and stained with hematoxylin and eosin.  
The microscopic features including the type of tumour, grade, histological 
patterns, cellular features, capsular invasion, lymphatic and vascular invasion, 
secondary changes, multicentricity and status of uninvolved thyroid were studied. 
The tumours were classified according to the WHO histological classification 
of thyroid tumours and the incidence of different histological types are noted. 
Among these,  47 cases of papillary thyroid carcinoma and its variants and 55 
cases of thyroid lesions which mimic it histologically (such as follicular adenoma, 
follicular carcinoma, Hurthle cell neoplasms, papillary hyperplasia and Hashimoto’s 
thyroiditis) are randomly selected and paraffin embedded tissue blocks from the 
representative sections are collected. 4 microns thick sections were cut and then 
transferred on to gelatin and chrome alum coated slides and subjected to antigen 
retrival using the Microwave technique with Citrate buffer solution. Immunostaining 
for Cytokeratin 19 and thyroglobulin were done on these samples using the BioGenex 
Super SensitiveTM Polymer-HRP IHC Detection System. The step by step procedure 
of immunohistochemistry is given in Annexure V. 
ANTIGEN VENDOR SPECIES DILUTION POSITIVE CONTROL 
Cytokeratin 19 BioGenex Mouse Ready to use Colonic carcinoma 
Thyroglobulin BioGenex Mouse Ready to use Follicular adenoma 
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 The immunostained slides were analysed for the presence of reaction, and the 
percentage of cells stained and the intensity of the reaction and the results were 
recorded. An estimation of positivity in more than 10 percent of tumour cells is 
considered as a positive reaction for Cytokeratin 19.  
The usefulness or role of immunohistochemistry in differentiating Papillary 
thyroid carcinoma and its variants from its histological mimickers is then evaluated 
and the results are compared with those reported in the literature. 
The statistical analysis was performed using statistical package for social 
science software version 19 and WinPepi software version 11.15. The correlation of 
immunoreactivity between papillary carcinoma and its mimickers was analysed using 
the Pearson chi square test. 
33
 OBSERVATION AND RESULTS 
During the study period from January 2009 to April 2011, out of 21535 
specimens received in the Institute of Pathology, Madras Medical College for 
histopathological examination, 1080 were thyroid specimens. Among these, there 
were 307 thyroid neoplasms (28.4%). The incidence of thyroid neoplasms among the 
total specimens received was 1.43%. 307 thyroid neoplasms formed the subject for the 
present study. 
TABLE 3: DISTRIBUTION OF THYROID LESIONS 
THYROID LESIONS NO OF CASES PERCENTAGE 
Nonneoplastic lesions 773 71.57 
Neoplastic lesions 307 28.43 
TOTAL 1080 100 
 
Of the neoplastic lesions, benign and malignant tumours were 112 (36.48%) 
and 195 (63.52%) respectively. 
TABLE 4: DISTRIBUTION OF THYROID NEOPLASMS 
THYROID NEOPLASMS NO OF CASES PERCENTAGE 
Benign neoplasms 112 36.48 
Malignant neoplasms 195 63.52 
TOTAL 307 100 
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 BENIGN NEOPLASMS 
Of the 112 benign neoplasms, there were 107 cases of Follicular adenoma and 
5 cases of Hyalinising trabecular adenoma.  
TABLE 5: DISTRIBUTION OF BENIGN THYROID NEOPLASMS 
BENIGN NEOPLASM NO OF CASES PERCENTAGE 
Follicular adenoma 107 95.54 
Hyalinising trabecular adenoma 5 4.46 
TOTAL 112 100 
 
Maximum incidence was observed during the 3rd and 4th decades of life 
accounting for 68 cases with a mean age of 36.47 years. 
TABLE 6: AGE DISTRIBUTION IN BENIGN NEOPLASMS 
BENIGN 
NEOPLASM 
AGE IN YEARS TOTAL 
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Follicular 
adenoma 
8 35 32 14 14 3 0 1 107 
Hyalinising 
trabecular 
adenoma 
1  1 3     5 
TOTAL 9 35 33 17 14 3 0 1 112 
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  Maximum incidence was seen in females with male:female ratio of 1:7. 
TABLE 7: SEX DISTRIBUTION IN BENIGN NEOPLASMS 
BENIGN NEOPLASM NO OF CASES TOTAL 
MALES FEMALES 
Follicular adenoma 14 93 107 
Hyalinising trabecular adenoma - 5 5 
TOTAL 14 98 112 
 
 
The size of the nodules ranged from 0.1 cm to 7 cm with a mean of 2.88 cm 
with majority of cases less than 4 cm. 
TABLE 8: SIZE OF NODULES IN BENIGN NEOPLASMS 
BENIGN NEOPLASM ≥ 2 cm 2 to 4 cm > 4 cm TOTAL 
Follicular adenoma 38 55 14 107 
Hyalinising trabecular adenoma 2 3 0 5 
TOTAL 40 58 14 112 
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 Among follicular adenoma, microfollicular variant was the most common. 
TABLE 9: DISTRIBUTION OF SUBTYPES OF FOLLICULAR ADENOMA 
FOLLICULAR ADENOMA NO OF CASES PERCENTAGE 
Microfollicular 43 40.19 
Micro & Macrofollicular 29 27.10 
Micro & Normofollicular 6 5.61 
Normofollicular 5 4.67 
Normo & Macrofollicular 11 10.28 
Macrofollicular 5 4.67 
Embryonal 2 1.87 
Hurthle cell variant 6 5.61 
TOTAL 107 100.00 
 
MALIGNANT MEOPLASMS 
Of the 195 malignant neoplasms, there were 176 Papillary carcinoma, 4 
follicular carcinoma, 2 anaplastic carcinoma, 5 each of medullary carcinoma and 
Poorly differentiated carcinoma and 1 each of Hurthle cell carcinoma, Squamous cell 
carcinoma and mixed papillary and medullary carcinoma. Papillary carcinoma formed 
the largest group forming 57.33% of all thyroid neoplasms followed by follicular 
adenoma (33.55%).  Among malignant thyroid lesions, papillary carcinoma 
constituted 90.26%. 
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 TABLE 10: DISTRIBUTION OF MALIGNANT THYROID LESIONS 
MALIGNANT NEOPLASM NO OF CASES PERCENTAGE 
Papillary carcinoma 176 90.26 
Follicular carcinoma 4 2.05 
Hurthle cell carcinoma 1 0.51 
Medullary Carcinoma 5 2.56 
Anaplastic carcinoma 2 1.03 
Insular carcinoma 5 2.56 
Squamous cell carcinoma 1 0.51 
Mixed PTC + MTC 1 0.51 
TOTAL 195 100 
 
 
Age distribution 
Thyroid malignancies were found to occur in all age groups from second to the 
eighth decade. The youngest patient was 13 years and the oldest patient was 82 years 
of age with a mean of 38.18 years and a male:female ratio of 1:5.09. They were 
observed to be common during the 3rd to 5th decades of life accounting for 141 cases 
(72.31%). 
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 TABLE 11: AGE DISTRIBUTION OF MALIGNANT THYROID NEOPLASMS 
MALIGNANT NEOPLASM AGE IN YEARS TOTAL 
1
1
-2
0
 
2
1
-3
0
 
3
1
-4
0
 
4
1
-5
0
 
5
1
-6
0
 
6
1
-7
0
 
7
1
-8
0
 
Papillary carcinoma 15 40 59 31 20 6 5 176 
Follicular carcinoma   1 1   1 1   4 
Hurthle cell carcinoma     1         1 
Medullary carcinoma   1 1   3     5 
Anaplastic carcinoma     1 1       2 
Insular carcinoma   3     1 1   5 
Squamous cell carcinoma         1     1 
Mixed PTC + MTC       1       1 
TOTAL 15 45 63 33 26 8 5 195 
 
TABLE 12: SEX DISTRIBUTION OF MALIGNANT THYROID NEOPLASMS 
MALIGNANT NEOPLASM NO OF CASES TOTAL 
MALES FEMALES 
Papillary carcinoma 29 147 176 
Follicular carcinoma  4 4 
Hurthle cell carcinoma  1 1 
Medullary Carcinoma 2 3 5 
Anaplastic carcinoma  2 2 
Insular carcinoma 1 4 5 
Squamous cell carcinoma  1 1 
Mixed PTC + MTC  1 1 
TOTAL 32 163 195 
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 The size of the nodules ranged from 0.1 cm to 11 cm with a mean of 2.94 cm. 
TABLE 13: SIZE OF NODULES IN MALIGNANT NEOPLASMS 
MALIGNANT NEOPLASM ≥ 2 cm 2 to 4 cm > 4 cm TOTAL 
Papillary carcinoma 80 72 24 176 
Follicular carcinoma 0 2 2 4 
Hurthle cell carcinoma 0 0 1 1 
Medullary carcinoma 1 1 3 5 
Anaplastic carcinoma 0 1 1 2 
Insular carcinoma 2 1 2 5 
Mixed PTC + MTC 1 0 0 1 
Squamous cell carcinoma 0 1 0 1 
TOTAL 84 78 33 195 
 
PAPILLARY CARCINOMA 
There were 176 cases of papillary carcinoma which constituted 57.33% of all 
thyroid neoplasms and 90.26% of all thyroid malignancies. Of these 58.52% were of 
the conventional type followed by the follicular variant (24.43%).  
TABLE 14: SUBTYPES OF PAPILLARY CARCINOMA 
SUBTYPE OF PTC NO OF CASES PERCENTAGE 
Conventional 103 58.52 
Microcarcinoma 10 5.68 
Follicular 43 24.43 
Encapsulated follicular 6 3.41 
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 SUBTYPE OF PTC NO OF CASES PERCENTAGE 
Diffuse follicular 3 1.70 
Solid 3 1.70 
Oncocytic 3 1.70 
Trabecular 2 1.14 
Nod Fas Stroma 1 0.57 
Dedifferentiated 2 1.14 
TOTAL 176 100 
 
More than 50% of patients were in the age range of 21 to 40 years (56.82%) 
with a peak incidence during 3rd to 5th decades of life (13 cases) and male:female 
ratio of 1:5.07.   
TABLE 15: AGE DISTRIBUTION OF PAPILLARY CARCINOMA 
SUBTYPE OF PTC AGE IN YEARS TOTAL 
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Conventional 10 23 34 20 12 2 2 103 
Microcarcinoma   2 3 2 3     10 
Follicular 4 8 17 6 4 2 2 43 
Encapsulated follicular   4 1 1       6 
Diffuse follicular     2     1   3 
Solid 1   1   1     3 
Oncocytic   2   1       3 
Trabecular     1 1       2 
Nod Fas Stroma   1           1 
Dedifferentiated           1 1 2 
TOTAL 15 40 59 31 20 6 5 176 
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 TABLE 16: SEX DISTRIBUTION OF PAPILLARY CARCINOMA 
SUBTYPE OF PTC NO OF CASES TOTAL 
MALES FEMALES 
Conventional 15 88 103 
Microcarcinoma 1 9 10 
Follicular 7 36 43 
Encapsulated follicular 2 4 6 
Diffuse follicular  3 3 
Solid 1 2 3 
Oncocytic 1 2 3 
Trabecular  2 2 
Nod Fas Stroma  1 1 
Dedifferentiated 2  2 
TOTAL 29 147 176 
 
TABLE 17: MACROSCOPIC FEATURES OF PAPILLARY CARCINOMA 
GROSS FEATURES NO OF CASES PERCENTAGE 
Unicentric 90 52.33 
Multicentric 80 46.51 
Entire thyroid involvement 2 1.16 
Solid nodule 153 87.93 
Cystic nodule 20 11.49 
Solid & cystic 1 0.57 
Capsulated nodules 121 69.54 
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 In the present study, unicentric cases were 80 (46.51%), multicentric cases 
were 90 (52.33%) and entire thyroid involvement in 2 cases (1.16%), 153 cases 
(87.93%) appeared solid on gross examination, 20 cases (11.49%) were cystic and 1 
(0.57%) was solid and cystic. 
Nodules varied in size from 0.1 cm to 10 cm with a mean of 2.78 cm 
Microscopically arborizing papillary processes with fibrovascular core was 
seen in the classic type. Ground glass nuclei were seen in 97.7% cases and psammoma 
bodies in 23.86% cases. Nuclear grooving was present in 98.9% cases, nuclear 
pseudoinclusions were seen in 24.5% cases. Capsule was present in 69.54% of cases, 
capsular invasion in 47.11% of capsulated PTC cases, lymphatic invasion in 29.89% 
and vascular invasion in 29.89% and necrosis in 11.36%. 
TABLE 18: MICROSCOPIC FEATURES OF PAPILLARY CARCINOMA 
MICROSCOPIC FEATURES NO OF CASES PERCENTAGE 
Arborizing papillary processes 123 69.89 
Ground glass nuclei 172 97.73 
Nuclear grooving 174 98.86 
Nuclear pseudoinclusions 43 24.5 
Psammoma bodies 42 23.86 
Capsular invasion 57 47.11 
Lymphatic invasion 52 29.89 
Vascular invasion 52 29.89 
Necrosis 20 11.36 
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 The most common associated lesion was Colloid goitre (38.07%) followed by 
Hashimoto’s thyroiditis (13.64%) and lymphocytic thyroiditis (9.09%). 
TABLE 19: ASSOCIATED LESIONS IN PAPILLARY CARCINOMA 
 ASSOCIATED LESION  NO OF CASES PERCENTAGE 
1. Adenomatous hyperplasia 3 1.70 
2. Colloid goitre 67 38.07 
3. Focal Hurthle cell changes 1 0.57 
4. Hashimoto’s thyroiditis 24 13.64 
5. Inflammatory cell infiltration with 
foreign body giant cell reaction 
1 0.57 
6. Lymphocytic thyroiditis 16 9.09 
7. Riedel’s thyroiditis 1 0.57 
8. Follicular adenoma 1 0.57 
9. Nil 8 4.55 
10. Normal 54 30.68 
TOTAL 176 100 
 
FOLLICULAR CARCINOMA 
There were 4 cases of follicular carcinoma accounting for 2.05% of malignant 
thyroid lesions. It occurred from 3rd to 7th decades of life and all were female patients. 
Grossly, 2 cases showed entire thyroid involvement while the other 2 cases were 
unicentric. The mean size was 5.25 cm. Microscopically, all 4 cases showed capsular 
invasion while 2 cases showed lymphovascular invasion. All 4 cases showed necrosis. 
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 POORLY DIFFERENTIATED CARCINOMA 
There were 5 cases of insular type of poorly differentiated carcinoma 
constituting 2.56% of thyroid malignancies. The mean age was 41 years with 
male:female ratio of 1:4. Grossly, the nodules varied from 1 cm to 8 cm size with a 
mean of 3.8 cm. One case was associated with papillary carcinoma.  
 
ANAPLASTIC CARCINOMA 
There were 2 cases of anaplastic carcinoma, both females with mean age of 43 
years and mean size of 7.25 cm. 
 
MEDULLARY CARCINOMA 
There were 5 cases of medullary carcinoma (2.56% of thyroid malignancies), 
with a mean age of 45.4 years and male:female ratio of 1:1.5. All cases showed Congo 
red positivity and one case had associated C cell hyperplasia. 
 
SQUAMOUS CELL CARCINOMA 
There was one case of primary squamous cell carcinoma in a 55 year old 
female. Microscopy showed sheets of malignant squamous cells along with bizarre 
tumour giant cells, necrosis, calcification and hyalinisation. The malignant cells were 
positive for cytokeratin and negative for thryoglobulin. 3 out of 5 ceervical lymph 
nodes showed metastatic deposits.  
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 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry for CK19 and Thyroglobulin was done for a total of 
102 cases, of which 47 were papillary carcinomas and 55 were the lesions 
histologically mimicking it. The PTC included 20 conventional, 17 follicular, 4 
encapsulated follicular, 2 diffuse follicular, 2 solid and 2 oncocytic variants. The 
histological mimickers included 22 FA, 4 HTA, 1 FTC, 2 insular carcinoma, 12 
papillary hyperplasia and 14 Hashimoto’s thyroiditis. 
Thyroglobulin showed diffuse positivity in all the 102 cases. 
Among PTC, all cases of conventional type showed diffuse strong positivity, 
whereas among the follicular variant, 70.59% showed strong positivity which was 
diffuse in 2 cases and focal in 10 cases, PTC EFV showed 75% positivity and the 
other variants showed 50% positivity. 
TABLE 20: CYTOKERATIN 19 IMMUNOSTAINING IN PAPILLARY CARCINOMA 
PAPILLARY CARCINOMA POSITIVE NEGATIVE % POSITIVE % NEGATIVE 
PTC Conventional 20 0 100 0 
PTC Follicular 12 5 70.59 29.41 
PTC Encapsulated follicular 3 1 75 25 
PTC Diffuse follicular 1 1 50 50 
PTC Solid 1 1 50 50 
PTC Oncocytic 1 1 50 50 
TOTAL 38 9 80.85 19.15 
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Among the histological mimickers of PTC, 95.45% of follicular adenoma 
showed negativity while 1 case showed a focal weak positivity. 2 cases of insular 
carcinoma showed positivity. 
 
TABLE 21: CYTOKERATIN 19 IMMUNOSTAINING IN PAPILLARY CARCINOMA MIMICS 
PTC MIMICKERS POSITIVE NEGATIVE % POSITIVE % NEGATIVE 
Follicular adenoma 1 21 4.55 95.45 
Hyalinising trabecular 
adenoma 
1 3 25 75 
Follicular carcinoma 0 1 0 100 
Insular carcinoma 2 0 100 0 
Papillary hyperplasia 1 11 8.33 91.67 
Hashimoto's thyroiditis 2 12 14.29 85.71 
TOTAL 7 48 12.73 87.27 
 
 
Cytokeratin 19 was positive in 80.85% of cases of papillary carcinoma, 
whereas it is positive only in 12.73% of cases of PTC mimickers and this difference is 
statistically significant with P<0.001. 
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 TABLE 22: COMPARISON OF CK19 IMMUNOSTAINING IN PAPILLARY CARCINOMA 
AND ITS HISTOLOGIC MIMICS 
 PTC PTC MIMICS TOTAL PEARSON’S CHI SQUARE TEST 
POSITIVE 38 7 45 
 
2=47.706   
P = 0.000 [5.0E-12] 
(Statistically significant) 
NEGATIVE 9 48 57 
TOTAL 47 55 102 
 
For a diagnosis of Papillary carcinoma, CK19 had a sensitivity of 80.85% and 
specificity of 87.27%. The predictive value of positivity was 84.44% and the 
predictive value of negativity was 84.21% while the false positivity rate was 12.73% 
and false negativity rate was 19.15%. The diagnostic accuracy was 84.31%. 
TABLE 23: CK19 IN THE DIAGNOSIS OF PAPILLARY CARCINOMA 
PARAMETER PERCENTAGE 
Sensitivity 80.85 % 
Specificity 87.27 % 
Predictive value of positivity 84.44 % 
Predictive value of negativity 84.21 % 
False positivity rate 12.73 % 
False negativity rate 19.15 % 
Diagnostic Accuracy 84.31 % 
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 DISCUSSION 
Out of a total of 1080 thyroid specimens received, 773 were Nonneoplastic and 
307 were neoplastic constituting 71.57% and 28.43% respectively.  A study by 
Sankaran V75 reviewed 127 cases and found the percentage of nonneoplastic and 
neoplastic lesions as 85.8% and 14.2% respectively. 
Out of the neoplasms, benign and malignant tumours were 112 (36.48%) and 
195 (63.52%) respectively. 
BENIGN NEOPLASMS 
Of the total 112 benign neoplasms, follicular adenoma was the most common 
lesion (107 cases) followed by hyalinising trabecular adenoma (5 cases). 
Maximum incidence was seen during the 3rd and 4th decades of life with female 
preponderance with a mean age of 36.47 years. Accetta et al76 found that benign thyroid 
lesions had a highest incidence during the fifth and sixth decades of life with a mean 
age of 51.8 years. 
The nodules varied in size from 0.1 cm to 7 cm with a mean of 2.88 cm and the 
majority (87.5%) were less than 4 cm in maximum diameter. 
Among follicular adenoma, microfollicular variant was more common 
accounting for 40.19% of FAs and embryonal type was the least common (1.87%). 
Hurthle cell adenoma constituted 6 cases (5.61%). 
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 MALIGNANT TUMOURS 
Carcinoma of the thyroid gland is a relatively rare disease accounting for 1 % of 
all malignant neoplasms.3  
In a study by Yeole BB et al, thyroid cancer constituted 1.3% of total cancers.77 
In our study, the incidence of thyroid malignancies among the total specimens received 
was 0.95%. Malignant tumours comprised 195 cases of a total of 307 neoplasms 
studied accounting for 63.52% of all thyroid neoplasms.  
Thyroid malignancies occur more commonly in females than in males. 
Ananthakrishnan et al78, Budhraja et al,79 Kishore et al80 and Freitag et al81 in their 
study found a higher incidence of thyroid carcinoma in females compared to males. The 
present study also showed a highly increased incidence in females with a male to 
female ratio of 1:5.09. 
TABLE 24: COMPARATIVE SEX RATIO OF MALIGNANT THYROID LESIONS 
STUDY MALE: FEMALE RATIO 
Ananthakrishnan et al78 1:3 
Budhraja et al79 1:2.2 
Kishore et al80 1:2.38 
Freitag et al81 1:5.46 
Present study 1:5.09 
 
Freitag et al81 also found that although the relation of 1 male to 5 females with 
thyroid carcinoma shows a clear dependence on sex, the histological type distribution is 
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 identical in both male and female. Therefore, several different factors seem to influence 
the development of thyroid carcinoma. One of these factors depends on sex and 
supports an increased development of carcinoma in female patients. Another factor 
doesn't depend on sex and causes different histological types. 
Thyroid malignancy can occur at any age. Papillary carcinomas occur at a 
relatively younger age group whereas follicular carcinomas occur at an older age group. 
Kishore et al80 and Selzer G et al82 observed a higher frequency of thyroid malignancies 
on the third to fifth decades of life. The present study showed a peak incidence of 
thyroid malignancies in the third to fifth decades of life accounting for 141 cases 
(72.31%). 
TABLE 25: COMPARISON OF AGE INCIDENCE OF THYROID CARCINOMA 
STUDY KISHORE ET AL80 SELZER G ET AL82 PRESENT STUDY 
1st decade - 3 - 
2nd decade 6 20 15 
3rd decade 24 68 45 
4th decade 31 84 63 
5th decade 11 40 33 
6th decade 10 19 26 
7th decade 7 14 8 
8th decade 1 6 5 
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 Histologically the most common type of thyroid carcinoma was papillary 
carcinoma. Different studies show varying incidence of histological types. 
Ananthakrishnan et al,78 Selzer G et al,82 Kishore et al,80 and Budhraja et al79 also found 
a high incidence of papillary carcinoma in their study accounting for 46.8%, 52.8%, 
47.5%, and 51.2% of all malignant thyroid neplasms respectively. In the present study 
also papillary carcinoma was the most common type accounting for 90.26% of all 
malignant thyroid neoplasms followed by medullary carcinoma and insular carcinoma. 
 
TABLE 26: PERCENTAGE INCIDENCE OF THYROID CARCINOMA IN DIFFERENT STUDIES 
STUDY ANANTHA
KRISHNAN 
ET AL78 
KISHORE 
ET AL80 
SELZER G 
ET AL82 
BUDHRAJA 
ET AL79 
FREITAG 
ET AL81 
PRESENT 
STUDY 
Papillary carcinoma 54.6 54.23 52.8 51.2 70.3 90.26 
Follicular carcinoma 32.5 22.9 30.7 23 18.47 2.05 
Hurthle cell Ca - - - - - 0.51 
Medullary Carcinoma 5.2 14.7 3.5 2.6 6.24 2.56 
Poorly differentiated 
& Anaplastic Ca 
3.9 3.27 10.2 20.5 4.99 3.60 
Lymphoma 1.2 - 1.6 - - - 
Squamous cell Ca - - - - - 0.51 
Mixed PTC + MTC - - - - - 0.51 
Others 2.6 4.9 1.2 2.7 - - 
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 PAPILLARY CARCINOMA 
Papillary carcinoma is the most common type of thyroid malignancy and is one 
of the few neoplasms where the prognosis is good with early diagnosis and proper 
management. Its incidence appears to have increased in the recent past which may be 
partially related to a change in the diagnostic criteria, particularly, the recognition of 
follicular variant. 
Papillary carcinoma accounted for 90.26% of all malignant neoplasms in the 
present study.  In a study by Lam AK et al,83 papillary carcinoma accounted for 72.8% 
of all primary thyroid cancers.  
There seems to be no age exemption for papillary carcinoma. It occurs in a 
relatively younger age group than follicular carcinoma. Kishore et al80 in their study 
found an increased incidence of papillary carcinoma in the third and fourth decade of 
life.  In the present study also a peak incidence of papillary carcinoma was noted in the 
third to fifth decades (130 out of 176 cases) which coincide with the other two studies. 
TABLE 27: AGE INCIDENCE OF PAPILLARY CARCINOMA 
STUDY  1ST 
DECADE  
2ND 
DECADE 
3RD 
DECADE  
4TH 
DECADE  
5TH 
DECADE  
6TH 
DECADE  
7TH 
DECADE  
8TH 
DECADE  
Srikhande et al84 1 7 28 23 21 25 15 3 
Carcangiu et al31 1 20 42 62 54 32 25 5 
Kishore et al80 - 1 7 12 1 4 4 4 
Present study  - 15 40 59 31 20 6 5 
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 Srikhande et al84 and Carcangiu et al31 noted a higher incidence of papillary 
carcinoma in females, with a male to female ratio of 1:1.9 and 1:2.6 respectively.  
 
In the present study, papillary carcinomas were seen to have a higher incidence 
in females than in males, the male to female ratio being 1:5.07 which is much higher 
than the other studies. 
 
 
TABLE 28: COMPARATIVE STUDY OF SEX INCIDENCE OF PAPILLARY CARCINOMA 
STUDY MALE: FEMALE RATIO 
Srikhande et al84 1:1.9 
Carcangiu et al31 1:2.6 
Lam AK et al83 1:3.26 
Present study 1:5.07 
 
 
Microscopically ten variants of papillary carcinoma were identified including the 
conventional type in the present study. The most common type was conventional (58.52 
%) followed by follicular variant (24.43%) and the least common was a case of PTC 
with nodular fasciitis like stroma.  
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 TABLE 29: COMPARISON OF SUBTYPES OF PAPILLARY CARCINOMA 
SUBTYPE OF PAPILLARY 
CARCINOMA 
PERCENTAGE OF CASES 
LAM AK ET AL83 
(N=652) 
MUZAFFAR M ET AL85 
(N=82) 
PRESENT STUDY 
(N=176) 
Conventional 46.01 70.7 58.52 
Microcarcinoma 27.76 - 5.68 
Follicular 17.64 15.9 24.43 
Encapsulated follicular - - 3.41 
Diffuse follicular 0.77 - 1.7 
Solid 0.77 - 1.7 
Oncocytic 0.15 2.4 1.7 
Trabecular - - 1.14 
Nod Fas Stroma 0.31 - 0.57 
Dedifferentiated 0.46 - 1.14 
Tall cell 3.99 3.7 - 
Diffuse sclerosing 1.84 - - 
Columnar cell 0.31 7.3 - 
 
In the present study, unicentric cases were 80 (46.51%), multicentric cases were 
90 (52.33%) and entire thyroid involvement in 2 cases (1.16%), the mean size was 
2.78cm, 153 cases (87.93%) appeared solid on gross examination, 20 cases (11.49%) 
were cystic and 1 (0.57%) was solid and cystic. 
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 Microscopically arborizing papillary processes with fibrovascular core was seen 
in the classic type. Ground glass nuclei were seen in 97.7% cases and psammoma 
bodies in 23.86% cases. In the study by Srikande et al, 69.9% cases showed ground 
glass nuclei and 46.3% cases showed psammoma bodies.  In a study by Chan JKC et 
al19 ground glass nuclei were seen in 84.3% of cases. Klink and Winship92 found 
psammoma bodies in 43% of cases of papillary carcinomas and only once in a review 
of 2153 benign thyroid lesions and thus they represent a very important clue to 
diagnosis.  
In the present study nuclear grooving was present in 98.9% cases, which is in 
concurrence with the study by Chan JKC.19 The present study showed nuclear 
pseudoinclusons in 24.5% cases in contrast to the study by Chan JKC19 where 46% 
cases showed nuclear pseudoinclusions. 
In the present study, capsule was present in 69.54% of cases, capsular invasion 
in 47.11% of capsulated PTC cases, lymphatic invasion in 29.89% and vascular 
invasion in 29.89% and necrosis in 11.36%. 
The most common associated lesion was Colloid goitre (38.07%) followed by 
Hashimoto’s thyroiditis (13.64%) and lymphocytic thyroiditis (9.09%). In a study by 
Selzer G et al,82 lymphocytic thyroiditis was found in association with 21 tumours 
(8.2%). 
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 FOLLICULAR CARCINOMA 
Follicular carcinoma accounts for 20% of all thyroid tumors. Budhraja et al, 
Kishore et al,80 Ananthakrishnan et al78 and Chan JKC et al19 observed that follicular 
carcinoma ranked next to papillary carcinoma in occurrence accounting for 23%, 
22.9%, 32.5% and 7.8% of cases respectively. In the present study, follicular carcinoma 
accounted for 2.05% of all thyroid malignancies. 
Follicular carcinomas occur in a relatively older age group compared to papillary 
carcinomas. Budhraja et al79 observed that follicular carcinoma occurred in an older age 
group. Kishore et al80 observed follicular carcinoma occurring from second to fifth 
decade. In the present study, follicular carcinomas were observed to occur from 3rd to 
7th decades and all the 4 patients were females. 
TABLE 30: SEX INCIDENCE OF FOLLICULAR CARCINOMA IN DIFFERENT STUDIES 
STUDY  MALE: FEMALE RATIO 
Selzer G et al82 1:3.6 
Kishore et al80 1:6 
Budhraja et al79 All 9 cases females 
Present study All 4 cases females 
 
Schmidth RJ et al86 observed both capsular and vascular invasion in all the 19 
cases which they reported. Pilotti et al87 found 29 cases of widely invasive follicular 
carcinoma in a study of 720 cases of non medullary carcinomas. In the present study, 
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 microscopically all 4 cases showed capsular invasion while 2 cases showed 
lymphovascular invasion.  
POORLY DIFFERENTIATED CARCINOMA 
Pilotti et al87 in their study of 720 cases of nonmedullary thyroid carcinomas 
found 4% cases of insular carcinoma. Volante et al88 observed 6.3% cases of poorly 
differentiated carcinoma. In the present study, there were 5 cases of insular type of 
poorly differentiated carcinoma constituting 2.56% of thyroid malignancies, which is 
less when compared to the other two studies. 
TABLE 31: COMPARISON OF INCIDENCE OF POORLY DIFFERENTIATED CARCINOMA 
STUDY PERCENTAGE INCIDENCE 
Pilotti et al87 4 % 
Volante et al88 6.3 % 
Present study 2.56 % 
 
Pilotti et al87 and Volante et al88 found the mean age of patients affected to be 53 
years and 57 years respectively. In the present study, the mean age was 41 years. 
ANAPLASTIC CARCINOMA 
Anaplastic carcinoma accounts for 5-10% of all primary malignant thyroid 
neoplasms. They occur in an older age group and are highly aggressive neoplasms. 
Kishore et al80 and Ananthakrishnan et al78 found 3.27% and 3.9% of cases of 
anaplastic carcinoma respectively. In the present study there were 2 cases of anaplastic 
carcinoma accounting for 1.03% of thyroid malignancies. Budhraja et al79 and Kishore 
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 et al80 observed a high incidence of anaplastic carcinoma in females. In the present 
study, both cases were females with mean age of 43 years. Microscopically, highly 
pleomorphic cells with increased mitotic figures were observed in the present study.  
MEDULLARY CARCINOMA 
Selzer G et al,82 Budhraja et al79 and Kishore et al80 observed the incidence of 
medullary carcinoma to be 3.5%, 2.6% and 14.7% respectively. In the present study, 
medullary carcinoma constituted 2.56% of all malignant thyroid neoplasms which 
compares well with the study by Budhraja et al. 
Kishore et al noticed a male:female ratio of 1:2 with all patients between the age 
group of 20 to 49 years. Budhraja et al observed a single case of medullary carcinoma 
in a 50 year male. In the present study, there were 5 cases with a male:female ratio of 
1:1.5 with a mean age of 45.4 years. 
Chong GC et al89 in their study of 139 cases of medullary carcinoma found 29 
cases of familial medullary carcinomas, these patients found to have a younger age at 
presentation. In the present study, no familial medullary carcinoma was observed. 
The present study had 5 cases of medullary carcinoma which on microscopy 
showed solid proliferation of cells with highly vascularised stroma and hyalinized 
collagen. All cases showed amyloid deposition which was confirmed by Congo red 
staining. One case was found to have associated C-cell hyperplasia.  
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 IMMUNOHISTOCHEMISTRY 
 
Thyroglobulin showed diffuse positivity in all the 102 cases, confirming them to 
be derived from thyroid follicular epithelium . 
 
PTC have been shown to express strong and diffuse immunoreactivity for CK19 
in 80 to 100% of cases.72 Unfortunately CK19 is also expressed focally in normal 
thyroid epithelium, Hashimoto’s thryoiditis and some benign tumours but the majority 
of the immunoreactivity occurred in areas of degeneration indicating the reactive nature 
of CK19 positivity. Nevertheless, diffuse positivity may have diagnostic value. In a 
study by Carol C Cheung et al,1 diffuse CK19 immunoreactivity is demonstrated in 
66% of papillary carcinomas and few cases of insular carcinomas and Hurthle cell 
carcinomas.  
 
In the present study, CK19 was positive in 80.85% of cases of papillary 
carcinoma, whereas it is positive only in 12.73% of cases of PTC mimics. Among PTC, 
all cases of conventional type showed diffuse strong positivity, whereas among the 
follicular variant, 70.59% showed strong positivity, PTC EFV showed 75% positivity 
and the other variants showed 50% positivity. 
 
Statistically significant correlation between Cytokeratin 19 and diagnosis of 
papillary carcinoma was observed in the present study similar to the various studies as 
given in Table 32. 
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 TABLE 32: COMPARISON OF CK19 IMMUNOREACTIVITY IN PAPILLARY CARCINOMA 
AND ITS MIMICS IN VARIOUS STUDIES 
STUDY CK19 PTC PTC 
MIMICS 
PEARSON'S CHI SQUARE TEST 
Carol C Cheung 
et al1 
Positive 91 18 2=47.619 
P = 0.000 [5.2E-12] 
(Statistically significant) 
Negative 47 74 
Manju L Prasad 
et al91 
Positive 48 9 2=42.610 
P = 0.000 [6.7E-11] 
(Statistically significant) 
Negative 19 53 
Dina el 
Demellawy et 
al71 
Positive 61 17 2=47.791 
P = 0.000 [4.7E-12] 
(Statistically significant) 
Negative 11 48 
Guyetant et al90 Positive 59 6 2=89.128   
P = 0.000 [3.7E-21] 
(Statistically significant) 
Negative 0 46 
Michel R Nasr 
et al73 
Positive 51 39 2=19.326   
P = 0.000 [1.1E-5] 
(Statistically significant) 
Negative 0 18 
Mustafa Kosem 
et al2 
Positive 60 22 2=47.280   
P = 0.000 [6.2E-12] 
(Statistically significant) 
Negative 0 30 
Present study Positive 38 7 2=47.706  
P = 0.000 [5.0E-12] 
(Statistically significant) 
Negative 9 48 
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 TABLE 33: COMPARISON OF CK19 IMMUNOREACTIVITY IN PAPILLARY CARCINOMA 
IN VARIOUS STUDIES 
Study Sensi-
tivity 
Speci-
ficity 
Predictive 
value of 
positivity 
Predictive 
value of 
negativity 
False 
+ve 
rate 
False 
–ve  
rate 
Diagnostic 
accuracy 
Carol C Cheung 
et al1 
65.94 80.43 83.49 61.16 19.57 34.06 71.74 
Manju L Prasad 
et al91 
71.64 85.48 84.21 73.61 14.52 28.36 78.29 
Dina El 
Demellawy et 
al71 
84.72 73.85 78.21 81.36 26.15 15.28 79.56 
Guyetant et al90 100 88.46 90.77 100 11.54 0 94.59 
Michel R Nasr et 
al73 
100 31.58 56.67 100 68.42 0 63.89 
Mustafa Kosem 
et al2 
100 57.69 73.17 100 42.31 0  80.36 
Present study 80.85 87.27 84.44 84.21 12.73 19.15 84.31 
 
Thus, there is a statistically significant association between CK19 positivity and 
papillary carcinoma with a diagnostic accuracy of 84.31%. Yet, there occurred a few 
false negative and false positive cases. However to get a diagnostic accuracy of 100%, 
additional panels like HBME-1, Galectin-3 and CITED-1 could be useful in the 
differentiation of papillary thyroid carcinoma from its histologic mimics as suggested 
by Carol C Cheung et al,1 Sandra Fischer et al72 and Michel R Nasr et al.73 
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 SUMMARY AND CONCLUSION 
 A total of 307 thyroid specimens received during the study period from January 
2009 to April 2011 were studied histomorphologically and were classified according to 
the WHO histological classification.  
 The incidence of thyroid neoplasms was 1.43% of all the specimens received in 
this institution and found to be more common among females (with male:female ratio 
of 1:7 in benign lesions and 1:5.09 in malignant lesions). 
 Among thyroid neoplasms, malignant lesions (63.52%) were more common 
compared to benign lesions (36.48%) with papillary carcinoma (57.33% of all 
neoplasms) as the most common neoplasm followed by follicular adenoma (33.55%). 
Among papillary carcinoma, conventional type was most common (58.52%) 
followed by follicular variant (24.43%). Multicentric PTC accounted for 46.51%. 
Ground glass nuclei were seen in 97.7%, psammoma bodies in 23.86%, Nuclear 
grooving in 98.9% cases and nuclear pseudoinclusons in 24.5% cases.  
Capsule was present in 69.54% of cases, capsular invasion in 47.11% of 
capsulated PTC cases, lymphatic invasion in 29.89% and vascular invasion in 29.89% 
and necrosis in 11.36%.  
The most common associated lesion in papillary carcinoma was Colloid goitre 
(38.07%) followed by Hashimoto’s thyroiditis (13.64%) and lymphocytic thyroiditis 
(9.09%). 
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 Immunohistochemical analysis of Cytokeratin 19 and thyroglobulin was done in 
102 cases selected randomly from cases of Papillary carcinoma and its histological 
mimickers (FA, HTA, FTC, Insular carcinoma, Papillary hyperplasia and Hashimoto’s 
thyroiditis). Thyroglobulin showed diffuse positivity in all the cases confirming them 
to be of follicular origin.  
CK19 was positive in 80.85% cases of papillary carcinoma whereas it is 
positive in 12.73% of lesions histologically mimicking papillary carcinoma and this 
difference was found to be statistically significant with P<0.001 which was in 
accordance with the other studies reported in the literature. CK19 was 80.85% 
sensitive and 87.27% specific for papillary carcinoma with a positive predictive value 
of 84.44% and a diagnostic accuracy of 84.31%. The false positivity rate was 12.73% 
and the false negativity rate was 19.15%. The results were similar to the studies 
reported in the literature. 
Though there is a statistically significant association between CK19 
immunoreactivity and the diagnosis of papillary thyroid carcinoma, there are often few 
false positive cases, especially in insular carcinoma and few cases of Hashimoto’s 
thyroiditis and false negative cases, especially in the follicular and solid variants of 
papillary carcinoma. 
Thus, Cytokeratin 19 when used alone, the diagnostic accuracy could be 84% 
and to get 100% accuracy, additional panels may be suggested such as HBME-1, 
Galectin-3 and CITED-1 as reported in the literature. This, when combined with 
molecular markers for RET/PTC and BRAF gene mutations, will be highly useful for a 
definitive diagnosis of papillary carcinoma, especially in difficult cases. 
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ANNEXURE I 
PROFORMA 
 
Case no. _____ 
   
Name  : _________________________ Date : ___-___-______ 
Age  : _______   years   IP. No : _____________ 
Sex  :     Male     Female  Unit : _____________ 
 
SPECIMEN SENT :     Total thyroidectomy    Right hemithyroidectomy 
        Neartotal thyroidectomy    Left hemithyroidectomy 
        Subtotal thyroidectomy 
GROSS FEATURES   : 
 One lobe    : Size   
   Nodules       Single     Multiple 
   Size of Nodule(s) 
   Other features 
 
 Other lobe : Size 
Nodules       Single     Multiple 
   Size of Nodule(s) 
   Other features 
 
MICROSCOPIC FEATURES : 
 Type of Tumour  : 
 Variant  : 
 Grade   :        Low grade     High grade 
HPE No. 
 Encapsulation  :     Present      Absent 
Capsular invasion :        Present     Absent 
Lymphatic invasion :     Present      Absent 
Vascular invasion :     Present      Absent 
Multicentricity :     Unicentric      Multicentric 
   Necrosis      Papillary processes      Psammoma bodies
    Ground glass nuclei    Nuclear grooving    
Other features  : 
 
Uninvolved Thyroid :     Normal      Hashimoto’s thyroiditis 
        Colloid goitre     Lymphocytic thyroiditis 
        C cell hyperplasia     Others 
 
Node status  : 
 
SPECIAL STAINS  : 
 
 
IMMUNOHISTOCHEMISTRY : 
Cytokeratin 19 
 
Thyroglobulin 
 
 
 
 
 
ANNEXURE II 
WHO HISTOLOGICAL CLASSIFICATION OF THYROID NEOPLASMS
 
(A) Thyroid adenoma and related tumors 
 Follicular adenoma 
 Hyalinizing trabecular tumor 
(B) Thyroid carcinomas 
 Papillary carcinoma 
 Follicular carcinoma 
 Poorly differentiated carcinoma 
 Undifferentiated (anaplastic) carcinoma 
 Squamous cell carcinoma 
 Mucoepidermoid carcinoma 
 Sclerosing mucoepidermoid carcinoma with eosinophilia 
 Mucinous carcinoma 
 Medullary carcinoma 
 Mixed medullary and follicular carcinoma 
 Spindle cell tumor with thymus-like differentiation 
 Carcinoma showing thymus-like differentiation 
(C) Other thyroid tumors 
 Teratoma 
 Primary lymphoma and plasmacytoma 
 Ectopic thymoma 
 Angiosarcoma 
 Smooth muscle tumors 
 Peripheral nerve sheath tumors 
 Paraganglioma 
 Solitary fibrous tumor 
 Follicular dendritic cell tumor 
 Langerhans cell histiocytosis 
(D) Secondary tumors 
ANNEXURE III 
TNM CLASSIFICATION OF THYROID CARCINOMAS 
 PRIMARY TUMOR (T)  
 TX Primary tumor cannot be assessed 
 T0 No evidence of primary tumor 
 T1 Tumor ≤2 cm greatest dimension, limited to the thyroid 
 T2 Tumor >2 cm but not >4 cm, limited to the thyroid 
 T3 Tumor >4 cm in greatest dimension, limited to the thyroid; or 
Any tumor with minimal extrathyroid extension (e.g., extension to sternothyroid 
muscle or perithyroid soft tissues) 
 T4a Tumor of any size extending beyond the thyroid capsule to invade subcutaneous 
soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve 
 T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal 
vessels  
 All anaplastic carcinomas are considered T4 tumors  
 T4a Intrathyroidal anaplastic carcinoma–surgically resectable  
 T4b Extrathyroidal anaplastic carcinoma–surgically unresectable 
REGIONAL LYMPH NODES (N) 
 NX Regional lymph nodes cannot be assessed 
 N0 No regional lymph node metastasis 
 N1a Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian 
lymph nodes 
 N1b Metastasis to unilateral, bilateral, or contralateral cervical or superior 
mediastinal lymph nodes 
DISTANT METASTASIS (M) 
 MX Distant metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
ANNEXURE IV 
PROGNOSTIC FACTORS IN PAPILLARY CARCINOMA 
1. AGES: Age, Grade, Extent of disease & Size 
2. AMES: 
PARAMETER LOW RISK HIGH RISK 
Age     Males 
            Females 
< 40 years 
< 50 years 
> 40 years 
> 50 years 
Distant Metastases No Yes 
Extent of primary disease Intrathyroidal Extrathyroidal 
Size < 5 cm > 5 cm 
 
3. MACIS: 
FACTORS SCORE 
Distant Metastasis Yes 3 
No 0 
Age (when tumour was 
identified) 
Less than 39 years 3.1 
Over 40 years 0.08 x Age 
Completeness of Surgical 
Resection 
Incomplete 1 
Complete 0 
Invasion into surrounding 
areas of neck 
Yes 1 
No 0 
Size of tumour 0.3 x Size in cm 
 
Sum of MACIS score < 6 6 to 6.99 7 to 7.99 > 8 
20 year survival 99 % 89 % 56 % 24 % 
 
4. DAEMS: DNA content, Age, Extent of disease, Metastasis & Size of tumour 
ANNEXURE V 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4μm thick sections are cut from formalin fixed paraffin embedded tissue samples 
and transferred on to gelatin-chrome alum coated slides. 
2. The sections are deparaffinized in xylene for 30 minutes x 2 changes. 
3. The sections are dehydrated with absolute alcohol for 5 minutes x 2 changes. 
4. The sections are washed in tap water for 10 minutes. 
5. The slides are then immersed in distilled water for 5 minutes. 
6. The slides are then kept in citrate buffer solution for 5 to 10 minutes. 
7. Heat induced antigen retrieval is done using microwave oven with citrate buffer 
solution for 20 minutes. 
8. The slides are then cooled to room temperature and washed in running tap water 
for 5 minutes. 
9. The slides are then rinsed in distilled water for 5 minutes. 
10. The slides are then washed with phosphate buffer solution for 5 minutes x 2 
changes. 
11. PEROXIDE BLOCK (to quench endogenous peroxidise in the tissue) is applied 
over the sections for 10 minutes. 
12. The slides are washed in phosphate buffer solution for 5 minutes x 2 changes. 
13. The sections are covered with POWER BLOCK (to block nonspecific antigen – 
antibody reactions) for 15 minutes. 
14. The sections are drained (without washing) and appropriate PRIMARY 
ANTIBODY applied over the sections and incubated for 45 minutes. 
15. The slides are washed in phosphate buffer for 5 minutes x 2 changes. 
16. The slides are covered with SUPER ENHANCER for 30 minutes (which increases 
the sensitivity of antigen – antibody reaction thereby enhancing the final reaction 
product). 
17. The slides are washed in phosphate buffer for 5 minutes x 2 changes. 
18. The slides are covered with SS LABEL (Secondary antibody from goat with 
tagged horse radish peroxidase enzyme) for 30 minutes. 
19. The slides are washed in phosphate buffer for 5 minutes x 2 changes. 
20. DAB substrate solution (prepared by diluting 1 drop of Diamino benzidine 
chromogen to 1 ml of DAB buffer) is then applied on the sections for 8 minutes. 
(DAB is cleaved by the enzyme to give the colored product at antigen sites) 
21. The slides are washed with phosphate buffer solution for 5 minutes x 2 changes. 
22. The slides are washed well in running tap water for 5 minutes. 
23. The sections are counterstained with Hematoxylin stain for 2 seconds (1 dip). 
24. The slides are washed in running tap water for 3 minutes. 
25. The slides are air dried, cleared with xylene and mounted with DPX. 
 
 
 
 
 
 
 
 
ANNEXURE VI 
 
 
MASTER CHART 
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
1 63/09 60 F PTC FOL M 2 SOL P + - - + A P P P NORMAL NIL Negative +++ 
2 170/09 35 F PTC SOL M 2 CYS & SOL P - - - - P P P A HASH NIL Negative ++ 
3 503/09 18 F FA MIC & MAC U 3.5 SOL P - - - - A A A A NORMAL NIL    
4 551/09 42 F PTC CON M 2.5 CYS P + - - - P P P A COLL GOIT LYM 
AGG 
NIL    
5 554/09 35 F PTC FOL U 3 SOL P + + + - A P P A NORMAL NIL    
6 611/09 25 F PTC CON U 2 SOL P - - - - P P P A COLL GOIT NIL    
7 734/09 40 M PTC FOL U 4 SOL P + - - - A P P A HASH NIL    
8 853/09 30 F PTC CON  2 SOL A  - - - P P P A NORMAL NIL    
9 1103/09 52 F PTC CON M 6.5 SOL P + - - - P P P P NORMAL NIL    
10 1195/09 27 M FA MIC M 2 SOL P - - - - A A A A NORMAL NIL Negative +++ 
11 1305/09 32 M PTC CON U 5 CYS P + - - - P P P P NORMAL NIL    
12 1318/09 55 F PTC CON M 4 SOL P - - - - P P P A COLL GOIT NIL    
13 1536/09 40 F PTC CON M 3.5 SOL A  + + + P P P A COLL GOIT NIL    
14 1688/09 26 M INSCA  M 8 SOL P + + + + A A A A COLL GOIT NIL    
15 1783/09 44 F PTC CON U 4 CYS P - - - - P P P P COLL GOIT NIL    
16 1851/09 25 F FA MIC U 2 SOL P - - - - A A A A NORMAL NIL Negative +++ 
17 1854/09 21 F PTC CON U 3.5 SOL P + - - - P P P A COLL GOIT NIL    
18 1957/09 39 F PTC CON M 4 SOL P + - - - P P P P COLL GOIT NIL    
19 1960/09 45 F PTC CON M 3 SOL P - - - - P P P A COLL GOIT NIL    
20 2025/09 35 F FA MIC & MAC U 4 SOL P - - - - A A A A HASH NIL    
21 2101/09 38 M FA MIC U 2 SOL P - - - - A A A A LYM THYR NIL Negative +++ 
22 2156/09 32 F FA MIC U 2.5 SOL P - - - - A A A A NORMAL NIL    
23 2502/09 38 F FA HUR U 4 SOL P - - - - A A A A NORMAL NIL Negative +++ 
24 2698/09 34 F FA MIC & MAC U 5 SOL P - - - - A A A A NORMAL NIL    
25 2797/09 40 F FA MIC U 2 SOL P - - - - A A A A NORMAL NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
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26 2881/09 29 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL Negative +++ 
27 2883/09 29 F FA MIC U 2.5 SOL P - - - - A A A A NORMAL NIL    
28 2936/09 24 F FA MIC U 2 SOL P - - - - A A A A NORMAL NIL    
29 3182/09 40 F PTC CON U 2.5 CYS P - - - - P P P A COLL GOIT NIL    
30 3202/09 65 M PTC DEDIF M 5 SOL P + + + + P P P A NIL NIL    
31 3412/09 26 F FA MIC & MAC U 0.1 SOL P - - - - A A A A NORMAL NIL    
32 3737/09 35 F FA MIC M 3.5 CYS P - - - - A A A A NORMAL NIL    
33 3822/09 20 F PTC CON U 4 SOL A  - - - P P P P NORMAL 1/1    
34 4223/09 15 F PTC SOL U 3 SOL P + - + - P P P A NORMAL NIL    
35 4435/09 28 F PTC CON U 2.5 SOL P - + + - P P P A NORMAL 1/1    
36 4470/09 45 M PTC CON U 1.5 SOL P + - - - P P P P NORMAL NIL    
37 4528/09 31 F FA MIC U 4.5 SOL P - - - - A A A A HASH NIL Negative +++ 
38 4669/09 22 F PTC CON U 1.5 SOL P - - - - P P P A HASH NIL    
39 4705/09 32 F FA MIC U 3 SOL P - - - - A A A A LYM THYR NIL    
40 4788/09 40 F PTC FOL M 2 SOL P - - - - A P P A COLL GOIT NIL    
41 4790/09 26 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
42 4799/09 57 F PTC CON M 2 SOL P - - - - P P P A HASH NIL    
43 4967/09 22 M FA MIC U 4 SOL P - - - - A A A A NORMAL NIL    
44 5007/09 38 F PTC CON M 1.5 SOL P - - - - P P P A COLL GOIT NIL    
45 5026/09 40 F PTC CON M 2 SOL P - - - - P P P A NORMAL NIL    
46 5038/09 46 F FA MIC & MAC U 5 SOL P - - - - A A A A NORMAL NIL    
47 5046/09 40 F PTC CON U 1.5 SOL P - - - - P P P A NORMAL NIL    
48 5250/09 57 M PTC CON M 3 SOL P - - + - P P P A COLL GOIT 2/19    
49 5367/09 25 F PTC CON M 3 SOL P - - - - P P P A NORMAL NIL    
50 5453/09 45 F PTC CON U 1.5 CYS P - - - - P P P A COLL GOIT NIL    
51 5520/09 65 M PTC CON        - P P P A NORMAL 1/5    
52 5529/09 26 M PTC FOL U 5 SOL P - - - - A P P A COLL GOIT NIL    
53 5574/09 65 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
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54 5623/09 45 F FA MIC U 2 CYS P - - - - A A A A NORMAL NIL    
55 5652/09 32 F PTC CON U 1.5 SOL A  - - - P P P P NORMAL NIL    
56 5710/09 34 F PTC CON M 1.75 SOL P - - - - P P P A HASH NIL    
57 5892/09 13 F HTA  U 2.5 SOL P - - - - A A A A NORMAL NIL    
58 5894/09 25 F PTC FOL U 2.5 CYS P + - - - A P P A LYM THYR NIL    
59 6007/09 26 F FA MIC U 3 SOL P - - - - A A A A NORMAL NIL    
60 6020/09 37 F PTC CON U 4.5 SOL A  - - - P P P A COLL GOIT NIL    
61 6021/09 33 F PTC MICRCA M 0.5 SOL A  - - - P P P A COLL GOIT NIL    
62 6077/09 42 F HTA  U 2.5 SOL P - - - - A A A A NORMAL NIL Negative +++ 
63 6122/09 32 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
64 6203/09 77 M PTC CON U 2 SOL A  - - - P P P A COLL GOIT NIL    
65 6223/09 17 F PTC FOL U 1 SOL A  + + - A P A A NORMAL 10/18    
66 6256/09 45 F FA MIC & MAC M 5 SOL P - - - - A A A A HASH NIL    
67 6257/09 27 F FA MIC U 3 SOL P - - - - A A A A NORMAL NIL    
68 6296/09 35 F PTC CON M 2.5 SOL A  - - - P P P A COLL GOIT 2/2    
69 6455/09 60 M FA MIC & MAC M 2 CYS P - - - - A A A A COLL GOIT NIL    
70 6540/09 82 F FA MIC M 2 SOL P - - - - A A A A NORMAL NIL    
71 6837/09 25 M PTC CON U 4 SOL P - - - - P P P A NORMAL NIL    
72 6946/09 29 F PTC CON U 1.5 SOL P - - - - P P P A LYM THYR NIL    
73 7030/09 21 F FA MIC & MAC U 1.5 SOL P - - - - A A A A NORMAL NIL Negative +++ 
74 7108/09 48 F PTC + 
MTC 
  2 SOL P + + + - P P P P COLL GOIT 11/11    
75 7119/09 78 F PTC CON U 3.5 CYS A  - - - P P P A COLL GOIT NIL    
76 7190/09 20 F FA MIC & MAC U 2 SOL P - - - - A A A A NORMAL NIL Negative +++ 
77 7210/09 23 F FA MIC U 4.5 SOL P - - - - A A A A NORMAL NIL Negative +++ 
78 7283/09 30 F FA MIC & MAC U 3 SOL P - - - - A A A A HASH NIL    
79 7298/09 41 F PTC FOL U 3 SOL A  - - - A P P A COLL GOIT NIL    
80 7304/09 34 F PTC CON M 2 SOL P - - - - P P P A NORMAL NIL    
81 7307/09 55 M MTC   5 SOL A  - - + A A A A COLL GOIT 2/2    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
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82 7342/09 50 M FA MIC U 6 SOL P - - - - A A A A COLL GOIT NIL    
83 7493/09 57 F MTC SPC  5 SOL A  - + + A A A A NORMAL NIL    
84 7496/09 60 F PTC MICRCA U 0.1 SOL A  + - - P P P A COLL GOIT 1/7    
85 7503/09 20 F PTC CON U 3 SOL P - - - - P P P P HASH NIL    
86 7590/09 30 F FA MAC U 4 SOL P - - - - A A A A NORMAL NIL Negative +++ 
87 7671/09 26 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
88 7678/09 24 M PTC EFV U 2.5 SOL P - - - - A P P A NORMAL NIL    
89 7719/09 32 F PTC FOL U 2 SOL P - - - - A P P A LYM THYR NIL    
90 7741/09 35 M PTC CON U 5 SOL P + + - - P P P P NORMAL 4/4    
91 7746/09 35 F PTC CON U 2 SOL P - - - - P P P A LYM THYR NIL    
92 7766/09 65 F FA MIC U 4 SOL P - - - - A A A A NORMAL NIL    
93 7773/09 46 F HTA  U 3 SOL P - - - - A A A A NORMAL NIL Negative ++ 
94 7856/09 32 M MTC   5 SOL P - - - - A A A A LYM THYR 9/9    
95 7868/09 65 M PTC CON M 1.5 SOL P - + + - P P P A NORMAL 7/7    
96 7871/09 38 F PTC FOL U 5 SOL A  + + + A P P A LYM THYR 2/5    
97 7876/09 58 F FA MIC U 5 SOL P - - - - A A A A NORMAL NIL    
98 7958/09 65 F FTC  ET 2.5 SOL P + + + + A A A A NORMAL NIL    
99 7971/09 42 M FA MIC & MAC U 1.5 SOL P - - - - A A A A NORMAL NIL    
100 8043/09 33 M PTC FOL U 5 SOL P - - - - A P P A NORMAL NIL Foc +++ +++ 
101 8044/09 19 F PTC FOL U 2 SOL P - - - - P P P A NORMAL NIL Foc ++ +++ 
102 8149/09 30 F FA MIC M 3 SOL P - - - - A A A A HASH NIL    
103 8253/09 23 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
104 8263/09 15 F PTC CON U 2 SOL A  - - - P P P P HASH 13/22    
105 8391/09 30 F FA MIC U 2 SOL P - - - - A A A A NORMAL NIL    
106 8446/09 30 M FA MIC U 2.5 SOL P - - - - A A A A COLL GOIT NIL    
107 8553/09 32 F PTC CON M 2.5 SOL P - - - - P P P P COLL GOIT NIL    
108 8575/09 29 F FA MIC & MAC U 4 SOL P - - - - A A A A LYM THYR 0/2    
109 8623/09 48 F PTC CON  2      - P P P A NORMAL NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
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110 8649/09 39 F PTC CON U 3 SOL A  - - - P P P A NORMAL NIL    
111 8733/09 38 F PTC FOL U 3.5 SOL P - - - - A P P A COLL GOIT NIL Foc ++ +++ 
112 59/10 29 F PTC CON U 2 CYS P + + + - P P P P COLL GOIT NIL    
113 68/10 20 F PTC ONC U 1 SOL P + + + - A P P A COLL GOIT 0/1 Negative +++ 
114 160/10 57 F PTC FOL U 2.5 SOL P + - - - A P P P COLL GOIT NIL    
115 164/10 33 F PTC CON M 3 SOL P - + + - P P P A HASH NIL Dif +++ +++ 
116 167/10 30 F PTC CON U 2.5 SOL P + + + - P P P A NORMAL NIL Dif +++ ++ 
117 168/10 28 F PTC EFV M 5 SOL P - - - - A P P A NORMAL NIL Negative +++ 
118 181/10 34 F PTC FOL U 3 SOL A  - - - P A P A NORMAL NIL    
119 234/10 54 F FA NOR M 0.5 SOL P - - - - A A A A HASH NIL    
120 248/10 45 F PTC FOL U 3 SOL A  - - - A P P A HASH 0/1 Negative +++ 
121 261/10 38 F PTC CON M 2 SOL P + + + - P P P A COLL GOIT NIL Dif ++ +++ 
122 370/10 30 F PTC FOL U 6 CYS P + - - - A P P A COLL GOIT TOX 
CHN 
NIL Foc ++ +++ 
123 512/10 23 F PTC FOL M 2.5 SOL P + + + + A P P A NORMAL NIL    
124 568/10 32 F FA NOR & MAC U 3 SOL P - - - - A A A A LYM THYR NIL    
125 580/10 47 F FA NOR & MAC M 4 CYS P - - - - A A A A NORMAL NIL    
126 598/10 30 F PTC CON U 3 SOL P - + + - P P P P LYM THYR 4/4    
127 692/10 19 F PTC CON M 1.5 SOL P + + + + P P P A NORMAL 20/20    
128 760/10 19 F PTC CON M 2 SOL P - - - - P P P A COLL GOIT 
ADEN HYP 
NIL    
129 822/10 34 F PTC TRAB U 3 SOL A  - - - P P P A LYM THYR NIL    
130 852/10 30 F FA NOR U 3 SOL P - - - - A A A A NORMAL NIL    
131 869/10 19 F PTC CON M 3 SOL P + - - + P P P A COLL GOIT 6/10    
132 884/10 32 M PTC FOL M 3 SOL P + - - - A P P A COLL GOIT NIL    
133 956/10 33 F FA MIC & NOR U 3 SOL P - - - - A A A A NORMAL NIL    
134 961/10 50 F ANTC  ET 11 SOL A  - - + A A A A NIL NIL    
135 970/10 30 F FA NOR & MAC M 3 CYS P - - - - A A A A LYM THYR NIL    
136 1015/10 40 F HURCA  U 5 SOL A  + + + A A A A COLL GOIT NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
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137 1043/10 42 F PTC CON M 1.5 SOL A  - - - P P P A NORMAL NIL    
138 1073/10 40 F PTC FOL M 3 SOL P - - - - A P P A NORMAL 0/2    
139 1079/10 30 F PTC FOL U 4 SOL P + - + - A P P A NIL NIL    
140 1108/10 57 F FA NOR & MAC U 3 SOL P - - - - A A A A NORMAL NIL    
141 1178/10 40 F FA MIC U 2 SOL P - - - - A A A A NORMAL NIL    
142 1193/10 30 F PTC CON M 2 SOL A  - + - P P P A COLL GOIT NIL Dif ++ +++ 
143 1422/10 25 F FA NOR U 3.5 SOL P - - - - A A A A NORMAL NIL    
144 1436/10 35 F PTC CON M 2 CYS P - - + - P P P P COLL GOIT PAP 
HYP 
NIL Foc +++ +++ 
145 1442/10 30 F MTC SMC  0.7 SOL A  + - - A A A A C CELL HYP 5/11    
146 1501/10 45 F PTC TRAB U 2 SOL P + - - - P P P A COLL GOIT NIL    
147 1615/10 34 F PTC CON M 3.5 SOL A  + + - P P P A LYM THYR NIL    
148 1677/10 38 F FA MIC M 3 SOL P - - - - A A A A COLL GOIT NIL    
149 1756/10 14 F PTC CON U 2.5 SOL P - - - - P P P A NORMAL NIL Dif +++ ++ 
150 1810/10 32 F PTC FOL M 3 SOL P + - - - A P P A COLL GOIT NIL    
151 2025/10 47 M PTC CON U 2 SOL P + + + - P P P A NORMAL NIL Dif ++ ++ 
152 2028/10 50 F PTC EFV ET 7 SOL P - - - - A A P A NORMAL NIL    
153 2242/10 23 M PTC EFV U 4 SOL P + + + + A P A A NORMAL NIL Dif +++ ++ 
154 2262/10 53 F PTC CON U 3 SOL P - - - - P P P P HASH NIL    
155 2296/10 39 F PTC CON M 1.5 SOL P + - - - P P P A HASH NIL Dif +++ +++ 
156 2368/10 40 F PTC FOL M 3.5 SOL P - - - - A P P A COLL GOIT NIL    
157 2409/10 32 F FA MIC & NOR U 2 SOL P - - - - A A A A NORMAL NIL Negative +++ 
158 2414/10 24 F FA MIC U 1 SOL P - - - - A A A A LYM THYR NIL Foc + +++ 
159 2581/10 26 F PTC CON M 2 SOL A  + + - P P P A HASH 6/9 Dif +++ +++ 
160 2689/10 65 M PTC FOL M 5 CYS P - - + - A P P A NORMAL NIL    
161 2692/10 55 F FTC  ET 10 SOL P + + + + A A A A NIL NIL Negative +++ 
162 2694/10 35 F PTC CON U 3 SOL A  + + + P P P A LYM THYR NIL    
163 2716/10 45 F FA MAC U 7 SOL P - - - - A A A A NORMAL NIL    
164 2733/10 42 F PTC CON M 2 SOL A  + - - P P P P NORMAL NIL Dif +++ ++ 
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
165 2748/10 55 F PTC CON U 6 SOL A  - + - P P P A HASH 0/3    
166 2751/10 38 F PTC DFV U 2 SOL P + - - - A P P A NIL NIL Negative ++ 
167 2809/10 60 M PTC SOL U 6 SOL P + + + - A A P A LYM THYR NIL Dif +++ +++ 
168 2877/10 32 F PTC DFV U 6 SOL A  - - + A P P A HASH NIL    
169 2941/10 33 F FA MAC U 2.5 CYS P - - - - A A A A COLL GOIT NIL    
170 3042/10 29 F PTC CON U 5 SOL P + + + - P P P P NORMAL 1/3 Dif +++ +++ 
171 3056/10 26 F FA MIC & MAC U 2 SOL P - - - - A A A A NORMAL NIL    
172 3076/10 38 F PTC CON M 2 SOL P + - - - P P P A COLL GOIT 
ADEN HYP 
NIL    
173 3136/10 25 F FA MAC U 2.5 SOL P - - - - A A A A NORMAL NIL    
174 3282/10 55 F FA NOR & MAC M 4 SOL P - - - - A A A A HASHT NIL    
175 3286/10 45 F HTA  U 1.5 SOL P - - - - A A A A NORMAL NIL Negative +++ 
176 3308/10 31 F FA MIC U 3.5 SOL P - - - - A A A A COLL GOIT NIL    
177 3324/10 29 F FA NOR U 1.5 SOL P - - - - A A A A COLL GOIT NIL    
178 3410/10 32 F FA MIC & NOR U 1 SOL P - - - - A A A A COLL GOIT 
ADEN HYP 
NIL    
179 3495/10 40 F FA NOR & MAC M 3 SOL P - - - - A A A A COLL GOIT 
ADEN HYP 
NIL    
180 3504/10 30 F INSCA  U 3 SOL A  + + + A A A A NIL NIL    
181 3515/10 35 F PTC EFV M 4 SOL P + - - - A P P P ADEN HYP NIL Dif ++ +++ 
182 3520/10 42 F FA HUR U 2 SOL P - - - - A A A A HASH NIL    
183 3561/10 40 F FA MIC U 3 SOL P - - - - A A A A NORMAL NIL    
184 3563/10 30 F PTC CON M 1.5 SOL A  - - - P P P A NORMAL NIL    
185 3640/10 45 F PTC CON M 3 SOL P + - - - P P P P HASH 1/1 Dif +++ +++ 
186 3687/10 61 M FA NOR & MAC U 4.5 SOL P - - - - A A A A NORMAL NIL    
187 3716/10 20 M FA MIC M 1 CYS P - - - - A A A A COLL GOIT NIL    
188 3765/10 48 M FA EMB U 3 SOL P - - - - A A A A NORMAL NIL Negative ++ 
189 3794/10 28 F FA NOR U 4 SOL P - - - - A A A A COLL GOIT NIL    
190 3807/10 55 F FA MIC & MAC U 3 SOL P - - - - A A A A COLL GOIT NIL    
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191 3846/10 40 F FA MIC & NOR U 4 CYS P - - - - A A A A NORMAL NIL    
192 3848/10 18 F FA MIC U 2.5 SOL P - - - - A A A A NORMAL NIL    
193 3898/10 24 F PTC NF M 4 SOL A  - - - P P P P NORMAL NIL    
194 3951/10 49 F PTC MICRCA M 0.5 SOL P - - - - P P P P INF FBGC NIL    
195 3954/10 35 F PTC CON U 3.5 CYS A  + + + P P P A NIL NIL    
196 3991/10 60 F FA MIC & NOR U 1.5 SOL P - - - - A A A A NORMAL NIL    
197 4082/10 40 F PTC CON M 5 SOL P + - - - P P P A COLL GOIT PAP 
HYP 
NIL    
198 4097/10 60 F FA HUR U 7 SOL P - - - - A A A A NORMAL NIL    
199 4154/10 50 F PTC CON U 4.5 SOL A  + + - P P P A NIL NIL    
200 4167/10 23 F FA NOR & MAC U 1.5 SOL P - - - - A A A A NORMAL NIL    
201 4192/10 45 F PTC FOL M 2.5 SOL A  + + - A P P A HASH 2/2 Foc +++ +++ 
202 4510/10 57 M PTC CON M 1.5 SOL P + + + + P P P A COLL GOIT 12/12 Dif +++ +++ 
203 4700/10 39 F PTC CON U 2.5 SOL A  + + - P P P P NORMAL NIL Dif +++ ++ 
204 4744/10 31 F PTC FOL U 4.5 SOL P + - - - A P P A NORMAL NIL Dif +++ +++ 
205 4758/10 23 M PTC MICRCA U 1 CYS P - - - - P P P A COLL GOIT NIL    
206 4765/10 37 F FA MIC & MAC U 1 SOL P - - - - A A A A COLL GOIT NIL Negative ++ 
207 4907/10 26 F PTC CON U 2 SOL A  - - - P P P A LYM THYR NIL    
208 5069/10 36 F FA MIC & MAC U 3 SOL P - - - - A A A A NORMAL NIL Negative +++ 
209 5070/10 18 F FA MIC U 4 SOL P - - - - A A A A NORMAL NIL Negative ++ 
210 5072/10 27 F FA MIC U 0.5 SOL P - - - - A A A A LYM THYR NIL Negative +++ 
211 5193/10 29 F PTC ONC U 3 SOL A  + + - A P P P NORMAL 1/1 Dif +++ ++ 
212 5211/10 43 F PTC CON M 3.5 SOL P - - - - P P P A HASH NIL Dif +++ +++ 
213 5255/10 37 F PTC CON M 3 SOL P - - - - P P P P COLL GOIT NIL Dif +++ +++ 
214 5262/10 32 F PTC FOL M 1.5 SOL P + + + - A P P A NORMAL NIL Foc ++ +++ 
215 5466/10 20 F PTC FOL U 1.5 SOL P - - - - A P P A NORMAL NIL Dif +++ ++ 
216 5581/10 54 F INSCA  M 6 SOL P + + + + A A A A NORMAL 0/10    
217 5839/10 50 M PTC ONC & CRIB M 3 SOL A  + + + A P P P LYM THYR 15/15    
218 5868/10 29 F PTC CON M 1.5 CYS P - - - - P P P P NORMAL NIL Dif +++ +++ 
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219 5884/10 30 F PTC FOL U 4 SOL P - - - - A P P A LYM THYR NIL Negative +++ 
220 6080/10 80 M PTC DEDIF U 5 SOL P + + - + A P P A NIL NIL    
221 6282/10 36 F FTC WD U 3.5 CYS P + - - + A A A A NORMAL NIL    
222 6442/10 15 F PTC CON U 1.5 SOL P - + + - P P P P COLL GOIT 5/5 Dif +++ +++ 
223 6489/10 25 F PTC FOL M 1 SOL P + - - - A P P A LYM THYR NIL    
224 6515/10 55 F SQCC   2.5 SOL A  + + + A A A A NIL 3/5    
225 6646/10 14 M FA MIC U 4.5 SOL P - - - - A A A A NORMAL NIL    
226 6730/10 47 F FA MIC U 2.5 SOL P - - - - A A A A NORMAL NIL Negative +++ 
227 6753/10 45 F PTC CON M 4 SOL P - - - - P P P P NORMAL NIL Dif +++ +++ 
228 6846/10 23 F FA MIC U 3.5 SOL P - - - - A A A A NORMAL NIL    
229 6977/10 26 F FTC WD U 5 SOL P + - - + A A A A NIL NIL    
230 7184/10 26 F PTC CON U 3 SOL P + + + - P P P P NORMAL NIL Dif +++ +++ 
231 7201/10 75 F PTC FOL M 3 SOL A  - - - P P P A NORMAL NIL Foc ++ +++ 
232 7333/10 55 F FA MIC & MAC M 2 CYS P - - - - A A A A COLL GOIT NIL Negative +++ 
233 7345/10 34 M FA MIC U 2 SOL P - - - - A A A A NORMAL NIL    
234 7356/10 65 F INSCA  U 1 SOL A  - - + A A A A COLL GOIT NIL Foc + ++ 
235 7618/10 45 F PTC MICRCA U 1 CYS A  - - - P P P A COLL GOIT NIL    
236 7710/10 59 M PTC CON M 3.5 SOL P - - - - P P P P HURTHLE 
CHANGES 
7/7    
237 7872/10 50 F PTC CON U 2.5 SOL P + - - - P P P A COLL GOIT NIL    
238 8175/10 27 F FA MIC M 2 SOL P - - - - A A A A COLL GOIT NIL    
239 8256/10 55 F FA HUR U 2 SOL P - - - - A A A A NORMAL NIL Negative +++ 
240 8261/10 53 F MTC ONC  4 SOL A  - - - A A A A ADEN HYP NIL    
241 8308/10 60 F PTC CON M 2 SOL A  - - - P P P A NORMAL 1/1    
242 8557/10 40 M PTC CON M 2.5 SOL A  - - - P P P A NORMAL 3/3    
243 8611/10 25 F PTC CON M 2 CYS A  - - - P P P P ADEN HYP NIL    
244 8766/10 55 F FA MAC U 4 CYS P - - - - A A A A COLL GOIT NIL    
245 8930/10 38 F PTC FOL U 2 SOL P - - - - A A P P HASH 0/1    
246 8939/10 71 M PTC FOL U 3 SOL P - - - - A P P A ADEN HYP NIL Negative +++ 
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
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GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
247 9014/10 30 F INSCA  M 1 SOL A  - - - A A A A HASH NIL Foc ++ ++ 
248 9035/10 52 F FA HUR U 6 CYS P - - - - A A A A COLL GOIT NIL Negative ++ 
249 9190/10 41 F PTC CON M 1.5 CYS P - - - - P P P A COLL GOIT NIL    
250 9194/10 55 F PTC CON U 2 SOL P - - - - P P P A HASH NIL    
251 9243/10 62 F PTC FOL  5 SOL P + + + + A P P A NIL NIL Negative +++ 
252 9370/10 55 F PTC CON M 4 CYS P - - - - P P P A COLL GOIT NIL    
253 9406/10 34 F FA MIC & MAC M 3 SOL P - - - - A A A A COLL GOIT NIL    
254 82/11 38 F PTC MICRCA M 0.5 SOL A  - - - P P P A COLL GOIT NIL    
255 192/11 48 F PTC CON M 1.5 CYS P - + + - P P P P COLL GOIT NIL    
256 235/11 36 F ANTC  U 3.5 SOL P + - - + A A A A COLL GOIT NIL    
257 279/11 55 F FA MIC U 3 SOL P - - - - A A A A COLL GOIT NIL    
258 433/11 40 F PTC CON M 2.5 SOL P - - - - P P P A COLL GOIT NIL    
259 515/11 45 F PTC CON M 2.5 SOL A  - - - P P P A HASH NIL    
260 589/11 57 F PTC MICRCA U 1 SOL P + - - - P P P A COLL GOIT 
ADEN HYP 
NIL    
261 590/11 32 F HTA  M 1.5 SOL P - - - - A A A A ONC ADEN HYP NIL Foc + +++ 
262 600/11 62 F PTC DFV ET 4 SOL A  + + + A P P A NIL 1/1 Foc ++ ++ 
263 663/11 45 F PTC CON U 10 SOL P + + - + P P P P NORMAL 10/12    
264 776/11 29 F PTC EFV U 3 SOL P + + + - P P P A COLL GOIT LYM 
AGG 
NIL Dif +++ ++ 
265 892/11 32 F PTC FOL M 3 SOL P + + + - A P P A COLL GOIT NIL Foc +++ +++ 
266 917/11 43 F FA NOR & MAC M 1 SOL P - - - - A A A A COLL GOIT NIL    
267 998/11 57 F PTC FOL U 6.5 SOL P + + + - A P P A RIEDELS NIL Foc +++ ++ 
268 1140/11 34 F FA MIC U 1.5 SOL P - - - - A A A A NORMAL NIL    
269 1165/11 38 F PTC MICRCA U 0.5 SOL A  - - - P P P P FA NIL    
270 1234/11 47 M PTC CON M 1.5 SOL A  + - - P P P P COLL GOIT 4/7    
271 1300/11 39 F PTC CON M 1.5 SOL P + + + + P P P P COLL GOIT TOX 
CHN 
NIL    
272 1310/11 26 F PTC CON U 1.5 SOL P + - - - P P P A NORMAL NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
273 1314/11 24 F PTC CON M 1.5 SOL A  + + - P P P A NORMAL NIL    
274 1368/11 50 F PTC FOL U 3.5 SOL P + + + - A P P A COLL GOIT 
ADEN HYP 
NIL Foc + ++ 
275 1521/11 58 M PTC CON U 5 SOL P + + + + P P P A LYM THYR NIL    
276 1527/11 28 F PTC FOL U 1 SOL A  - - - A P P A COLL GOIT NIL    
277 1578/11 57 F PTC MICRCA M 0.5 SOL P - - - - P P P A HASH NIL    
278 1736/11 37 M FA MIC U 2 SOL P - - - - A A A A COLL GOIT NIL    
279 1741/11 55 F FA MIC & MAC M 2 CYS P - - - - A A A A COLL GOIT NIL    
280 1778/11 39 M FA MIC & MAC U 4.5 CYS P - - - - A A A A COLL GOIT NIL    
281 1800/11 19 F FA NOR & MAC U 3 CYS P - - - - A A A A NORMAL NIL    
282 1802/11 25 F FA EMB  &  HUR M 2 SOL P - - - - A A A A COLL GOIT NIL Negative ++ 
283 1808/11 40 F FA MIC & NOR U 2 SOL P - - - - A A A A COLL GOIT NIL    
284 1948/11 22 F PTC CON U 1.5 SOL P - - - - P P P P COLL GOIT NIL    
285 1949/11 37 F PTC CON U 2 SOL A  - - - P P P A COLL GOIT TOX 
CHN 
NIL    
286 1992/11 33 F FA MIC & MAC M 2.5 SOL P - - - - A A A A COLL GOIT NIL    
287 2004/11 46 M PTC FOL M 1 SOL P + - - - A P P A COLL GOIT NIL    
288 2128/11 45 F FA MIC & MAC U 4 SOL P - - - - A A A A COLL GOIT NIL    
289 2138/11 40 F FA HUR U 2 CYS P - - - - A A A A NORMAL NIL    
290 2245/11 22 F FA MIC & MAC U 3.5 SOL P - - - - A A A A NORMAL NIL    
291 2281/11 39 F FA MIC U 3 SOL P - - - - A A A A NORMAL NIL    
292 2410/11 48 F PTC FOL M 4 CYS P + + + - A P P A HASH NIL    
293 2467/11 22 F PTC FOL U 2 SOL P + - - - A P P A LYM THYR NIL    
294 2589/11 29 F PTC CON M 1.5 SOL P - - - - P P P A COLL GOIT NIL    
295 2620/11 24 F FA NOR & MAC U 4.5 SOL P - - - - A A A A ONC ADEN HYP NIL    
296 2696/11 35 F PTC CON M 2 SOL A  - - - P P P A COLL GOIT NIL    
297 2736/11 48 M PTC CON U 2 SOL P + + + - P P P A HASH NIL    
298 2737/11 27 F PTC MICRCA U 0.5 SOL A  - - - P P P P COLL GOIT NIL    
299 2767/11 47 F FA MIC M 0.5 CYS P - - - - A A A A NORMAL NIL    
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
300 2773/11 48 F FA MIC U 3 SOL P - - - - A A A A NORMAL NIL    
301 2778/11 20 F PTC CON M 2 SOL A  + - - P P P P COLL GOIT NIL    
302 2851/11 34 F PTC CON M 4 SOL P - - - - P P P A COLL GOIT NIL    
303 2857/11 19 F FA MIC U 3 CYS P - - - - A A A A COLL GOIT NIL    
304 3033/11 38 F PTC FOL U 3 SOL P - - - - A P P A COLL GOIT NIL    
305 3105/11 55 F PTC FOL & SOL M 2 SOL A  - + + A P P A COLL GOIT NIL    
306 3131/11 19 F PTC CON U 1.5 SOL P - - - - P P P A HASH NIL    
307 3138/11 40 F PTC CON M 1.5 SOL A  + - - P P P A COLL GOIT 5/28    
308 890/09 34 F HASH         - A A A A NIL NIL Negative +++ 
309 979/09 30 F PAPHYP         - P A A A NIL NIL Negative +++ 
310 1281/09 22 F HASH         - A A A A NIL NIL Negative +++ 
311 1325/09 27 F HASH         - A A A A NIL NIL Negative +++ 
312 1537/09 25 F PAPHYP         - P A A A NIL NIL Negative +++ 
313 1833/09 49 F HASH         - A A A A NIL NIL Negative +++ 
314 1852/09 33 F HASH         - A A A A NIL NIL Negative +++ 
315 2174/09 45 F PAPHYP         - P A A A NIL NIL Negative +++ 
316 2307/09 24 M PAPHYP         - P A A A NIL NIL Negative +++ 
317 2622/09 45 F PAPHYP         - P A A A NIL NIL Negative +++ 
318 3015/09 42 F HASH         - A A A A NIL NIL Negative +++ 
319 6379/09 45 F HASH         - A A A A NIL NIL Negative +++ 
320 6721/09 35 F HASH         - A A A A NIL NIL Negative +++ 
321 872/10 45 F HASH         - A A A A NIL NIL Negative +++ 
322 1625/10 35 F HASH         - A A A A NIL NIL Negative +++ 
323 2186/10 40 F PAPHYP         - P A A A NIL NIL Foc + +++ 
324 2325/10 50 F PAPHYP         - P A A A NIL NIL Negative +++ 
325 2879/10 38 F PAPHYP         - P A A A NIL NIL Negative +++ 
326 3055/10 40 F PAPHYP         - P A A A NIL NIL Negative +++ 
327 3138/10 30 F HASH         - A A A A NIL NIL Foc ++ +++ 
S.No. HPE NO. AGE SEX DIAGNOSIS NODULE CAPS CI LI VI NEC PAP CL 
NUC 
GRV PSAM REST OF 
THYROID 
LNS CK19 TG 
TYPE VARIANT NO SIZE APP 
328 3468/10 28 F PAPHYP         - P A A A NIL NIL Negative +++ 
329 3699/10 57 M PAPHYP         - P A A A NIL NIL Negative +++ 
330 3705/10 34 F PAPHYP         - P A A A NIL NIL Negative +++ 
331 6652/10 55 F HASH         - A A A A NIL NIL Negative +++ 
332 7249/10 45 F HASH         - A A A A NIL NIL Foc ++ +++ 
333 9349/10 27 F HASH         - A A A A NIL NIL Negative +++ 
 
KEY TO MASTER CHART 
+ - Weak positivity 
++ - Moderate positivity 
+++ - Strong positivity 
A - Absent 
ADEN HYP - Adenomatous hyperplasia 
ANTC - Anaplastic thyroid carcinoma 
APP - Gross appearance 
C HYP - C cell hyperplasia 
CAPS - Capsule 
CI - Capsular invasion 
CK19 - Cytokeratin 19 
CL NUC - Ground glass nuclei (Nuclear clearing) 
COLL GOIT - Colloid goitre 
COLL GOIT ADEN HYP - Colloid goitre with focal adenomatous hyperplasia 
COLL GOIT LYM AGG - Colloid goitre with focal lymphoid aggregates 
COLL GOIT PAP HYP - Colloid goitre with focal papillary hyperplasia 
COLL GOIT TOX CHN - Colloid goitre with focal toxic changes 
CON - Conventional 
CRIB - Cribriform variant 
CYS - Cystic 
DEDIF - Dedifferentiated variant 
DFV - Diffuse follicular variant 
Dif - Diffuse positivity 
EFV - Encapsulated follicular variant 
EMB - Embryonal variant 
ET - Entire thyroid involvement 
FA - Follicular adenoma 
FA - Follicular adenoma 
Foc - Focal positivity 
FOL - Follicular variant 
FTC - Follicular thyroid carcinoma 
GRV - Nuclear grooving 
HASH - Hashimotos thyroiditis 
HASHT - Hashitoxicosis 
HTA - Hyalinising trabecular adenoma 
HUR - Hurthle cell variant 
HURCA - Hurthle cell carcinoma 
HURTHLE CHANGES - Hurthle cell changes 
INF FBGC - Dense inflammatory infiltrate & foreign body giant 
cell reaction 
INSCA - Insular carcinoma 
LI - Lymphatic invasion 
LNS - Lymph node status 
LYM THYR - Lymphocytic thyroiditis 
M - Multicentric 
MAC - Macrofollicular variant 
MIC - Microfollicular variant 
MICRCA - Microcarcinoma 
MTC - Medullary thyroid carcinoma 
NEC - Necrosis 
NF - Nodular fasciitis like stroma 
NOR - Normofollicular variant 
NORMAL - Normal 
ONC - Oncocytic variant 
ONC ADEN HYP - Oncocytic adenomatous hyperplasia 
P - Present 
PAP - Papillary processes 
PAPHYP - Papillary hyperplasia 
Pos - Positive 
PSAM - Psammoma bodies 
PTC - Papillary thyroid carcinoma 
PTC+MTC - Mixed papillary and medullary thyroid carcinoma 
RIEDELS - Riedels thyroiditis 
SMC - Small cell variant 
SOL - Solid 
SPC - Spindle cell variant 
SQCC - Squamous cell carcinoma 
TG - Thyroglobulin 
TRAB - Trabecular variant 
U - Unicentric 
VI - Vascular invasion 
WD - Well differentiated 
 
BENIGN THYROID NEOPLASMS 
 
 
 
Figure 1: Follicular adenoma gross appearance 
 
 
 
 
 
 
 
 
Figure 2: Microfollicular type of follicular 
adenoma (H&E x100) 
 
 
 
 
Figure 3: Micro and normofollicular type of 
follicular adenoma (H&E x100) 
 
 
 
 
 
 
Figure 4: Hurthle cell type of follicular adenoma 
(H&E x400) 
 
 
 
 
Figure 5: Hyalinising trabecular adenoma 
presenting as a capsulated well defined 
homogenous gray tan solid nodule with 
coexisting colloid nodule 
 
 
Figure 6: Hyalinising trabecular adenoma (H&E 
x100) 
 
PAPILLARY THYROID CARCINOMA 
 
 
 
Figure 7: Macroscopic appearance of papillary 
carcinoma 
 
 
 
 
Figure 8: Papillary carcinoma presenting as 
isthmic nodule 
 
 
 
 
Figure 9: Multicentric papillary carcinoma with 
areas of necrosis 
 
 
 
 
Figure 10: Papillary microcarcinoma 
presenting as a tiny solid area (arrow) within 
a nodular colloid goiter 
 
 
 
 
 
Figure 11: Papillary carcinoma - Solid variant 
 
 
 
Figure 12: Lymph node metastasis of 
papillary thyroid carcinoma presenting as a 
multicystic mass with a solid portion 
showing projection of papillary processes 
into the cystic space  
  
 
Figure 13: Conventional type of papillary 
carcinoma with arborising papillary processes 
(H&E x100) 
 
 
 
 
 
 
 
 
 
 
Figure 14: Papillary carcinoma with characteristic 
nuclear features (H&E x400) 
 
 
 
 
 
Figure 15: Papillary carcinoma showing capsular 
invasion (H&E x40) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Papillary carcinoma showing 
psammoma bodies 
 
 
 
 
 
Figure 17: Papillary carcinoma associated with 
Hashimoto's thyroiditis (H&E x100) 
 
 
 
Figure 18: Whole mount view of papillary 
carcinoma metastasis within 
sternocleidomastoid muscle 
 
 
 
 
Figure 19: Papillary microcarcinoma 
surrounded by normal thyroid parenchyma 
(H&E x40) 
 
 
 
 
 
 
 
 
 
Figure 20: Follicular variant of papillary carcinoma 
showing predominantly follicular pattern (H&E 
x100) 
 
 
 
 
 
Figure 21: Follicular variant of papillary 
carcinoma with characteristic nuclear features 
(H&E x400) 
 
 
 
 
 
 
 
 
Figure 22: Unencapsulated follicular variant of 
papillary carcinoma (H&E x100) 
 
 
 
 
 
Figure 23: Solid variant of papillary carcinoma - 
islands of tumour cells traversed by delicate 
fibrovascular septae (H&E x100) 
 
 
Figure 24: Focal cribriform pattern in solid variant 
of papillary carcinoma (H&E x100) 
 
  
 
 
 
Figure 25: Oncocytic variant of papillary carcinoma 
(H&E x400) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Papillary carcinoma with exuberant 
nodular fasciitis like stroma (H&E x40) 
 
 
 
 
 
 
 
Figure 27: Papillary carcinoma with exuberant 
nodular fasciitis like stroma (H&E x100) 
 
 
 
Figure 28: Papillary carcinoma dedifferentiated 
type with bizarre pleomorphic giant tumour cells 
with prominent nucleoli and increased mitotic 
figures some of them showing abnormal mitoses 
(H&E x400) 
 
 
 
 
 
FOLLICULAR THYROID CARCINOMA 
 
 
Figure 29: Follicular carcinoma replacing entire 
thyroid with areas of necrosis and hemorrhage 
 
 
 
 
 
Figure 30: Follicular carcinoma showing invasion 
into adjacent normal thyroid parenchyma  
(H&E x40) 
 
 
 
Figure 31: Follicular carcinoma showing capsular 
invasion (H&E x40) 
 
 
 
 
 
 
Figure 32: Follicular carcinoma showing capsular 
invasion (H&E x100) 
 
 
 
Figure 33: Hurthle cell carcinoma grossly 
appearing as homogenous gray white infiltrative 
mass 
 
 
Figure 34: Hurthle cell carcinoma microscopy 
(H&E x100) 
MEDULLARY THYROID CARCINOMA 
 
 
Figure 35: Gross appearance of medullary 
carcinoma involving one lobe of thyroid 
 
 
 
 
 
 
 
Figure 36: Medullary carcinoma showing sheets 
and nests of polygonal to spindle shaped tumour 
cells with round to oval nuclei (H&E x100) 
 
 
 
 
 
 
 
 
Figure 37: Tumour cells showing stippled 
chromatin (H&E x400) 
 
 
 
 
 
Figure 38: Loosely cohesive tumour cells 
(H&E x400) 
 
 
 
 
 
 
 
 
 
Figure 39: Tumour cells with amyloid (H&E x100) 
 
 
 
Figure 40: Amyloid showing Congo Red positivity 
(x100) 
 IMMUNOHISTOCHEMISTRY 
 
 
CYSTIC PAPILLARY CARCINOMA 
 
PAPILLARY HYPERPLASIA 
 
 
 
Figure 41: Cystic papillary carcinoma 
conventional type. (H&E x100) 
 
 
 
 
 
 
 
 
Figure 42: Papillary hyperplasia in a colloid goitre. 
(H&E x100) 
 
 
 
 
Figure 43: CK19 diffuse strong positivity in cystic 
papillary carcinoma. (x100) 
 
 
 
Figure 44: CK19 negativity in Papillary hyperplasia. 
(x100) 
 
 
 
 
 
PTC CONVENTIONAL HYALINISING TRABECULAR ADENOMA 
 
 
 
Figure 45: Papillary carcinoma conventional type  
showing arborising papillary processes. (H&E x100) 
 
 
 
 
 
Figure 46: Hyalinising trabecular adenoma. 
(H&E x100) 
 
 
 
Figure 47: CK19 diffuse strong immunoreactivity in 
conventional type of papillary carcinoma. (x100) 
 
 
 
 
 
Figure 48: CK19 negativity in Hyalinising trabecular 
adenoma. (x100) 
 
 
Figure 49: Thyroglobulin positivity in conventional 
type of papillary carcinoma (x100) 
 
 
Figure 50: Thyroglobulin positivity in hyalinising 
trabecular adenoma (x100) 
  
PTC FOLLICULAR VARIANT 
 
FOLLICULAR ADENOMA 
 
 
Figure 51: Follicular variant of papillary carcinoma 
(H&E x100) 
 
 
 
 
 
Figure 52: Follicular adenoma (H&E x100) 
 
 
 
 
Figure 53: CK19 diffuse strong positivity in 
follicular variant of papillary carcinoma. (x100) 
 
 
 
 
 
 
Figure 54: CK19 negativity in Follicular adenoma. 
(x100) 
 
 
Figure 55: Thyroglobulin positivity in follicular 
variant of papillary carcinoma (x200) 
 
 
Figure 56: Thyroglobulin positivity in follicular 
adenoma (x200) 
PTC FOLLICULAR VARIANT FOLLICULAR CARCINOMA 
 
 
 
Figure 57: Follicular variant of papillary carcinoma. 
(H&E x100) 
 
 
 
 
 
Figure 58: Follicular carcinoma. (H&E x100) 
 
 
 
Figure 59: CK19 diffuse strong positivity in 
follicular variant of papillary carcinoma. (x100) 
 
 
 
 
 
Figure 60: CK19 negativity in follicular carcinoma. 
(x200) 
 
 
 
Figure 61: Thyroglobulin positivity in follicular 
variant of papillary carcinoma (x200) 
 
 
Figure 62: Thyroglobulin positivity in follicular 
carcinoma (x100) 
PTC ONCOCYTIC VARIANT 
 
HURTHLE CELL ADENOMA 
 
 
Figure 63: Oncocytic variant of papillary carcinoma. 
(H&E x100) 
 
 
 
 
 
Figure 64: Hurthle cell adenoma. (H&E x100) 
 
 
 
Figure 65: CK19 diffuse strong positivity in 
oncocytic variant of papillary carcinoma. (x100) 
 
 
 
 
 
Figure 66: CK19 negativity in Hurthle cell adenoma. 
(x100) 
 
 
 
Figure 67: Thyroglobulin positivity in oncocytic 
variant of papillary carcinoma (x200) 
 
 
Figure 68: Thyroglobulin positivity in follicular 
adenoma (x100) 
  
PTC SOLID VARIANT INSULAR CARCINOMA 
 
 
 
Figure 69: Solid variant of papillary carcinoma. 
(H&E x100) 
 
 
 
 
 
Figure 70: Insular carcinoma. (H&E x100) 
 
 
 
Figure 71: CK19 diffuse strong positivity in solid 
variant of papillary carcinoma. (x100) 
 
 
 
 
 
Figure 72: CK19 focal positivity in insular 
carcinoma. (x100) 
 
 
 
Figure 73: Thyroglobulin positivity in solid variant 
of papillary carcinoma (x200) 
 
 
Figure 74: Thyroglobulin positivity in insular 
carcinoma (x100) 
 
  
PTC WITH LYMPHOCYTIC 
INFILTRATION 
 
 
 
HASHIMOTO’S THYROIDITIS 
 
 
 
Figure 75: Papillary carcinoma with lymphocytic 
infiltration. (H&E x40) 
 
 
 
 
 
 
 
 
Figure 76: Hashimoto’s thyroiditis. (H&E x100) 
 
 
 
Figure 77: CK19 diffuse strong positivity in 
papillary carcinoma with lymphocytic infiltration. 
(x200) 
 
 
 
Figure 78: CK19 negativity in Hashimoto’s 
thyroiditis. (x100) 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 79: Immunohistochemistry  Reagents using Super SensitiveTM Polymer HRP IHC Detection System. 
 
ABSTRACT 
HISTOMORPHOLOGICAL STUDY OF THYROID NEOPLASMS WITH SPECIAL 
REFERENCE TO PAPILLARY THYROID CARCINOMA AND ITS NEOPLASTIC 
HISTOLOGICAL MIMICKERS 
BACKGROUND AND OBJECTIVES: More than 95% of thyroid neoplasms arise from 
follicular epithelial cells. Papillary carcinoma has an excellent long term prognosis. Yet, at 
times, its diagnostic nuclear features remain controversial and its distinction from its 
histological mimickers may sometimes be difficult. Immunohistochemistry might be of 
immense help in such situations. The present study aims to histologically classify all thyroid 
neoplasms and to study the histomorphological characteristics and to evaluate the expression 
of Cytokeratin 19 and thyroglobulin in cases of papillary thyroid carcinoma and its 
histological mimickers. 
METHODS: 307 thyroid neoplasms received from January 2009 to April 2011 were studied 
histomorphologically and classified according to WHO classification. 47 cases of papillary 
thyroid carcinoma and its variants and 55 cases of its histological mimickers are randomly 
selected and cytokeratin 19 and thyroglobulin immunoreactivity were evaluated and its role 
in differentiating papillary carcinoma and its variants from its histological mimickers is then 
evaluated. 
RESULTS: The incidence of thyroid neoplasms was 1.43% of which papillary carcinoma 
was the most common, among which, conventional type was most common followed by 
follicular variant. Multicentric lesions were seen in 46.51%, nuclear clearing in 97.7%, 
nuclear grooving in 98.9% and psammoma bodies in 23.86%. The most common associated 
lesion was Colloid goitre (38.07%) followed by Hashimoto’s thyroiditis (13.64%).  
Thyroglobulin showed diffuse positivity in all cases confirming them to be of 
follicular origin. CK19 was positive in 80.85% cases of papillary carcinoma and in 12.73% of 
its histological mimickers and this difference was found to be statistically significant with 
P<0.001. CK19 was 80.85% sensitive, 87.27% specific for papillary carcinoma with a 
diagnostic accuracy of 84.31%. 
CONCLUSION: Though there is a statistically significant association between CK19 
immunoreactivity and papillary carcinoma, there are often few false positive and false 
negative cases. Thus, Cytokeratin 19 when used alone, the diagnostic accuracy could be 84% 
and to get 100% accuracy, additional panels including HBME-1, Galectin-3 and CITED-1 
will be highly useful for a definitive diagnosis of papillary carcinoma, especially in difficult 
cases. 
KEY WORDS: Papillary thyroid carcinoma, Cytokeratin 19, Thyroid neoplasms, 
Immunohistochemistry 
